[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2206
1. Tomita N, Kodaira T, Tachibana H, Nakamura T, Nakahara R, Inokuchi H, Shibamoto Y: Helical tomotherapy for brain metastases: dosimetric evaluation of treatment plans and early clinical results. Technol Cancer Res Treat; 2008 Dec;7(6):417-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helical tomotherapy for brain metastases: dosimetric evaluation of treatment plans and early clinical results.
  • The purpose of this study was to evaluate the feasibility and treatment plans of intensity-modulated radiation therapy using helical tomotherapy (HT) for brain metastases.
  • Twenty-three patients with 1 to 4 brain metastases were treated with HT.
  • In combination with whole-brain radiotherapy (simultaneous plans), metastatic lesions, and the whole brain were treated with 50 Gy and 30 Gy, respectively, in 10 fractions, with a simultaneous integrated boost technique.
  • In patients treated for brain metastases alone (focal plans), metastatic lesions were treated with 35 or 37.5 Gy in 5 fractions.
  • One patient with a huge tumor (34.0 cc) and WHO performance status 3 treated with focal plans experienced severe headache, requiring prolongation of the treatment time, and died at 8 days after completion of treatment.
  • HT is a viable non-invasive technique for treatment of brain metastases and achieves high accuracy in terms of dose conformity and homogeneity.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Neoplasms / pathology. Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain / radiation effects. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Radiation Oncology / methods. Radiometry / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19044320.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Noël G, Mazeron JJ: [Reirradiation in primary or secondary brain tumors]. Cancer Radiother; 2010 Oct;14(6-7):421-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reirradiation in primary or secondary brain tumors].
  • The purpose of this review was to analyze data available on reirradiation for high-grade glioma or brain metastasis.
  • In brain metastases, total brain irradiation seems useful if metastases are multiple and the patient in good condition.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Cranial Irradiation. Glioma / radiotherapy
  • [MeSH-minor] Adolescent. Adrenal Cortex Hormones / therapeutic use. Adult. Aged. Aged, 80 and over. Brain / radiation effects. Brain Edema / drug therapy. Brain Edema / etiology. Carcinoma / radiotherapy. Carcinoma / secondary. Carcinoma / surgery. Child. Child, Preschool. Clinical Trials as Topic. Dose Fractionation. Humans. Middle Aged. Neoplasm Recurrence, Local / radiotherapy. Prognosis. Radiation Injuries / drug therapy. Radiation Injuries / etiology. Radiation Injuries / prevention & control. Radiosurgery. Radiotherapy / adverse effects. Radiotherapy / methods. Radiotherapy Dosage. Radiotherapy, Conformal. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.
  • (PMID = 20797888.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


3. Adachi Y, Yagishita A: Gangliogliomas: Characteristic imaging findings and role in the temporal lobe epilepsy. Neuroradiology; 2008 Oct;50(10):829-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Ganglioglioma is an uncommon neoplasm of the central nervous system, most frequently seen in the temporal lobe, and usually associated with medically refractory epilepsy in children and young adults.
  • Mass effects were not seen in any of the ten tumors without cystic components.
  • One patient showed tumor recurrence.
  • In 23 cases, epileptogenicity was confirmed in the tumors by intraoperative electrocorticogram.
  • CONCLUSION: A tumor presenting isointensity to gray matter on T1-WI without mass effects in the medial temporal lobe in a young patient with temporal lobe epilepsy (TLE) might be the characteristic imaging of temporal lobe ganglioglioma.
  • However, such tumors are not always associated with epileptogenicity, even if a ganglioglioma is found in a patient with TLE.
  • Therefore, we need to investigate the hippocampus, white matter abnormalities of the ipsilateral and contralateral anterior temporal lobe, and other focal lesions closely.
  • [MeSH-major] Brain Neoplasms / complications. Brain Neoplasms / pathology. Epilepsy, Temporal Lobe / etiology. Epilepsy, Temporal Lobe / pathology. Ganglioglioma / complications. Ganglioglioma / pathology. Temporal Lobe / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Contrast Media. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2004 Jul 1;101(1):146-55 [15222000.001]
  • [Cites] Neuro Oncol. 2003 Jul;5(3):188-96 [12816725.001]
  • [Cites] Neuroradiology. 2007 Apr;49(4):307-15 [17205313.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):173-83 [12241112.001]
  • [Cites] J Neurosurg. 2005 Apr;102(3 Suppl):288-93 [15881752.001]
  • [Cites] Adv Neurol. 1999;81:153-64 [10609012.001]
  • [Cites] Radiographics. 2001 Nov-Dec;21(6):1533-56 [11706224.001]
  • [Cites] Surg Neurol. 1998 Apr;49(4):445-8 [9537666.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1994 Dec;57(12):1497-502 [7798980.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 May;24(5):829-34 [12748079.001]
  • [Cites] Arq Neuropsiquiatr. 2006 Sep;64(3A):613-8 [17119805.001]
  • [Cites] AJR Am J Roentgenol. 2000 Mar;174(3):859-62 [10701639.001]
  • [Cites] Clin Radiol. 2008 Jan;63(1):80-91 [18068794.001]
  • [Cites] Acta Neurol Scand. 2004 Feb;109(2):126-31 [14705975.001]
  • [Cites] Neuroradiology. 2006 Jul;48(7):460-4 [16645843.001]
  • (PMID = 18516598.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


Advertisement
4. Julià-Sapé M, Acosta D, Majós C, Moreno-Torres A, Wesseling P, Acebes JJ, Griffiths JR, Arús C: Comparison between neuroimaging classifications and histopathological diagnoses using an international multicenter brain tumor magnetic resonance imaging database. J Neurosurg; 2006 Jul;105(1):6-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison between neuroimaging classifications and histopathological diagnoses using an international multicenter brain tumor magnetic resonance imaging database.
  • OBJECT: The aim of this study was to estimate the accuracy of routine magnetic resonance (MR) imaging studies in the classification of brain tumors in terms of both cell type and grade of malignancy.
  • METHODS: The authors retrospectively assessed the correlation between neuroimaging classifications and histopathological diagnoses by using multicenter database records from 393 patients with brain tumors.
  • Each tumor category was compared with the corresponding histopathological diagnoses by dichotomization.
  • In routine reporting of MR imaging examinations, tumor types and grades were classified with a high specificity (85.2-100%); sensitivity varied, depending on the tumor type and grade, alone or in combination.
  • In neuroepithelial tumors, sensitivity was inversely related to the precision in reporting of grade and cellular origin; "glioma" was a frequent neuroimaging classification associated with higher sensitivity in the corresponding category.
  • The PPVs varied among categories, in general being greater than their prevalence in this dataset.
  • This study targets the need for noninvasively increasing sensitivity in categorizing most brain tumor types while retaining high specificity, especially in the differentiation of high- and low-grade glial tumor classes.
  • [MeSH-major] Brain Neoplasms / classification. Brain Neoplasms / pathology. Magnetic Resonance Imaging. Neoplasms, Nerve Tissue / classification. Neoplasms, Nerve Tissue / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Child. Child, Preschool. Databases, Factual. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16874886.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


5. Rajaraman P, Brenner AV, Neta G, Pfeiffer R, Wang SS, Yeager M, Thomas G, Fine HA, Linet MS, Rothman N, Chanock SJ, Inskip PD: Risk of meningioma and common variation in genes related to innate immunity. Cancer Epidemiol Biomarkers Prev; 2010 May;19(5):1356-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The etiology of meningioma, the second most common type of adult brain tumor in the United States, is largely unknown.

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 AACR
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):976-86 [19223558.001]
  • [Cites] J Immunol. 2009 Mar 1;182(5):3131-8 [19234210.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1651-8 [19423540.001]
  • [Cites] Neurotherapeutics. 2009 Jul;6(3):427-35 [19560733.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2649-58 [10594860.001]
  • [Cites] Neurosurgery. 2000 Nov;47(5):1185-95 [11063113.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):79-86 [11150357.001]
  • [Cites] Cancer Lett. 2002 Dec 15;188(1-2):103-7 [12406554.001]
  • [Cites] Genet Epidemiol. 2003 Dec;25(4):360-6 [14639705.001]
  • [Cites] Nature. 2003 Dec 18;426(6968):789-96 [14685227.001]
  • [Cites] J Anat. 2005 Sep;207(3):265-9 [16185251.001]
  • [Cites] Nat Rev Immunol. 2005 Nov;5(11):866-79 [16261174.001]
  • [Cites] Immunol Rev. 2006 Oct;213:195-212 [16972905.001]
  • [Cites] Pharmacogenet Genomics. 2006 Nov;16(11):783-8 [17047486.001]
  • [Cites] Am J Epidemiol. 2007 Mar 1;165(5):477-85 [17182979.001]
  • [Cites] Histol Histopathol. 2007 Dec;22(12):1387-98 [17701919.001]
  • [Cites] J Natl Cancer Inst. 2007 Oct 17;99(20):1544-50 [17925535.001]
  • [Cites] PLoS Genet. 2008 Aug;4(8):e1000166 [18846228.001]
  • [Cites] Dement Geriatr Cogn Disord. 2008;26(3):247-50 [18841008.001]
  • [Cites] PLoS One. 2009;4(4):e5360 [19390683.001]
  • (PMID = 20406964.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01CO12400; United States / Intramural NIH HHS / / Z99 CA999999; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS184299; NLM/ PMC3169167
  •  go-up   go-down


6. Sathornsumetee S, Reardon DA: Targeting multiple kinases in glioblastoma multiforme. Expert Opin Investig Drugs; 2009 Mar;18(3):277-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme (GBM), the most common primary malignant brain tumor in adults, is associated with high mortality.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19243279.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors
  • [Number-of-references] 137
  •  go-up   go-down


7. Wadasadawala T, Trivedi S, Gupta T, Epari S, Jalali R: The diagnostic dilemma of primary central nervous system melanoma. J Clin Neurosci; 2010 Aug;17(8):1014-1017
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Melanomas are malignant neoplasms of melanocytes developing predominantly in the skin, but occasionally arising from eyes, mucous membranes, and the central nervous system (CNS).
  • The CNS can be affected by a spectrum of melanocytic lesions ranging from diffuse neurocutaneous melanosis, to a focal and benign neoplasm (melanocytoma), and to an overtly malignant tumor (melanoma).
  • [MeSH-major] Brain Neoplasms / pathology. Cerebellopontine Angle / pathology. Melanoma / pathology. Parietal Lobe / pathology
  • [MeSH-minor] Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Male. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20627582.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


8. Cecener G, Tunca B, Egeli U, Bekar A, Guler G, Tolunay S, Aksoy K: FHIT gene sequence variants and reduced Fhit protein expression in glioblastoma multiforme. Cell Mol Neurobiol; 2010 Mar;30(2):301-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Additionally, the level of Fhit protein expression in tissues of 48 tumors was assessed by immunohistochemistry (IHC).
  • Moreover, it was observed that Fhit protein expression was reduced in 87.5% of tumors.
  • In conclusion, the reduction or loss of Fhit protein expression by genetic alterations or epigenetic mechanisms in GBM might be associated with brain tumorigenesis.
  • [MeSH-major] Acid Anhydride Hydrolases / genetics. Acid Anhydride Hydrolases / metabolism. Genetic Variation. Glioblastoma / genetics. Glioblastoma / metabolism. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Base Sequence. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Female. Humans. Male. Middle Aged. Molecular Sequence Data. Polymorphism, Single-Stranded Conformational. Sequence Analysis, DNA

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Teratog Carcinog Mutagen. 1998;18(6):279-91 [10052563.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Head Neck. 2000 Sep;22(6):591-8 [10941161.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Jun;75 Suppl 2:ii2-11 [15146033.001]
  • [Cites] Teratog Carcinog Mutagen. 2002;22(3):205-15 [11948631.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Apr;21(4):281-9 [9559339.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Tumori. 2007 Nov-Dec;93(6):604-7 [18338497.001]
  • [Cites] J Neurooncol. 2007 May;82(3):263-9 [17151929.001]
  • [Cites] J Neurosurg. 1996 Mar;84(3):442-8 [8609556.001]
  • [Cites] Cancer Lett. 2006 Jan 28;232(1):27-36 [16225988.001]
  • [Cites] Cancer Res. 1997 Feb 1;57(3):504-12 [9012482.001]
  • [Cites] Cancer Res. 1997 Apr 15;57(8):1435-7 [9108441.001]
  • [Cites] Oncol Rep. 1999 Mar-Apr;6(2):345-8 [10023002.001]
  • [Cites] Brain Res Brain Res Rev. 2004 Jul;45(3):143-63 [15210301.001]
  • [Cites] Int J Oncol. 2000 Nov;17(5):1031-5 [11029509.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Nucleic Acids Res. 2006 Mar 06;34(5):1317-25 [16522644.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1605-14 [15073846.001]
  • [Cites] Cell. 1996 Apr 5;85(1):17-26 [8620533.001]
  • [Cites] Tumori. 2007 Nov-Dec;93(6):597-603 [18338496.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Jun;119(2):139-45 [10867150.001]
  • [Cites] Int J Cancer. 1998 Apr 13;76(2):176-81 [9537577.001]
  • [Cites] Nucleic Acids Res. 2005 Sep 07;33(16):5053-62 [16147989.001]
  • [Cites] Teratog Carcinog Mutagen. 2002;22(1):31-40 [11754385.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2638-41 [9205070.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Jun;95(2):153-8 [9169033.001]
  • [Cites] Cancer Res. 1997 Sep 1;57(17):3664-8 [9288768.001]
  • [Cites] Ai Zheng. 2003 Jan;22(1):50-4 [12561436.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):214-21 [11902576.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2256-67 [9187130.001]
  • [Cites] Cell. 1996 Feb 23;84(4):587-97 [8598045.001]
  • [Cites] Lancet Oncol. 2002 Dec;3(12):748-54 [12473516.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):228-33 [14734474.001]
  • [Cites] Adv Anat Pathol. 2003 Jul;10(4):212-7 [12826827.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):137-60 [15674475.001]
  • (PMID = 19760177.001).
  • [ISSN] 1573-6830
  • [Journal-full-title] Cellular and molecular neurobiology
  • [ISO-abbreviation] Cell. Mol. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


9. Gerevini S, Mandelli C, Cadioli M, Scotti G: Diagnostic value and surgical implications of the magnetic resonance imaging in the management of adult patients with brachial plexus pathologies. Surg Radiol Anat; 2008 Mar;30(2):91-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value and surgical implications of the magnetic resonance imaging in the management of adult patients with brachial plexus pathologies.
  • The bpMRI provides a topographic localization of the tumour showing the nerve dislocations or infiltration by the neoplasm.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Contrast Media. Electromyography. Female. Gadolinium DTPA. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brachial Plexus Injuries.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hand Clin. 2005 Feb;21(1):13-24 [15668062.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Sep;18(8):1429-31 [9296182.001]
  • [Cites] J Neurosurg. 2002 Apr;96(3 Suppl):277-84 [11990835.001]
  • [Cites] Hand Clin. 2005 Feb;21(1):39-46, vi [15668064.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Nov-Dec;17(10):1932-6 [8933882.001]
  • [Cites] Neurosurg Focus. 2004 May 15;16(5):E2 [15174822.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):285-7 [9527135.001]
  • [Cites] AJNR Am J Neuroradiol. 1998 Jun-Jul;19(6):1011-23 [9672005.001]
  • [Cites] Skeletal Radiol. 2003 Jul;32(7):375-87 [12851788.001]
  • [Cites] AJR Am J Roentgenol. 2000 Aug;175(2):417-22 [10915686.001]
  • [Cites] AJR Am J Roentgenol. 1993 Aug;161(2):373-9 [8392788.001]
  • [Cites] Clin Radiol. 2004 Sep;59(9):767-74 [15351241.001]
  • [Cites] Brain. 1951 Dec;74(4):491-516 [14895767.001]
  • [Cites] Neuroimaging Clin N Am. 2004 Feb;14(1):59-85, vii-viii [15177257.001]
  • [Cites] J Hand Surg Br. 2001 Jun;26(3):183-91 [11386764.001]
  • [Cites] Radiology. 1987 Dec;165(3):763-7 [3685357.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Oct;18(9):1733-42 [9367325.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Mar;25(3):431-40 [15037469.001]
  • [Cites] Hand Clin. 2005 Feb;21(1):25-37 [15668063.001]
  • [Cites] Brain. 1999 Jul;122 ( Pt 7):1383-90 [10388803.001]
  • [Cites] Radiology. 2000 Mar;214(3):837-42 [10715054.001]
  • [Cites] J Am Acad Orthop Surg. 2005 Oct;13(6):382-96 [16224111.001]
  • [Cites] Hand Clin. 2005 Feb;21(1):1-11 [15668061.001]
  • [Cites] Top Magn Reson Imaging. 2004 Apr;15(2):113-25 [15269614.001]
  • [Cites] Bratisl Lek Listy. 2003;104(10):291-9 [15055727.001]
  • [Cites] Morphologie. 2002 Jun;86(273):31-4 [12224390.001]
  • [Cites] J Neurol Sci. 2004 Apr 15;219(1-2):15-21 [15050432.001]
  • [Cites] Invest Radiol. 2006 Jul;41(7):553-9 [16772848.001]
  • (PMID = 18094920.001).
  • [ISSN] 0930-1038
  • [Journal-full-title] Surgical and radiologic anatomy : SRA
  • [ISO-abbreviation] Surg Radiol Anat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


10. Tabernero MD, Maillo A, Gil-Bellosta CJ, Castrillo A, Sousa P, Merino M, Orfao A: Gene expression profiles of meningiomas are associated with tumor cytogenetics and patient outcome. Brain Pathol; 2009 Jul;19(3):409-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiles of meningiomas are associated with tumor cytogenetics and patient outcome.
  • Cytogenetic analysis is a powerful tool for predicting recurrence in meningiomas, even among histologically benign/grade I tumors.
  • Despite this, no study has been reported in which the impact of tumor cytogenetics on the gene expression profiles (GEP) has been analyzed in meningiomas.
  • Here, we analyzed the GEP of 47 tumors and correlated them with the most clinical relevant cytogenetic subgroups of meningiomas, as confirmed through the analysis of 172 patients.
  • Overall, our results show a clear association between the clinically relevant cytogenetic subgroups of meningiomas including diploid tumors (n = 18), isolated -22/22q- (n = 12), del(1p36) alone (n = 4) and complex karyotypes associated with del(1p36) and/or -14q (n = 13) and their GEP.
  • Accordingly, based on the expression of 85 genes (40 of which were coded in the altered chromosomes used for patient stratification) the cytogenetic class of the tumor could be predicted with an error of <1%, a clear association being found between the GEP and patient outcome (P = 0.03) but not tumor histopathology.
  • [MeSH-major] Cytogenetic Analysis. Gene Expression Profiling. Meningeal Neoplasms / genetics. Meningioma / genetics. Neoplasm Recurrence, Local / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18637901.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


11. Stall B, Zach L, Ning H, Ondos J, Arora B, Shankavaram U, Miller RW, Citrin D, Camphausen K: Comparison of T2 and FLAIR imaging for target delineation in high grade gliomas. Radiat Oncol; 2010 Jan 28;5:5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Normal structures, clinical tumor volume (CTV) and planning tumor volume (PTV) were then defined on the T2 and FLAIR sequences.
  • A Venn diagram analysis was performed for each pair of tumor volumes as well as a fractional component analysis to assess the contribution of each sequence to the union volume.
  • For each patient the tumor volumes were compared in terms of total volume in cubic centimeters as well as anatomic location using a discordance index.
  • The overlap of the tumor volumes with critical structures was calculated as a measure of predicted toxicity.
  • For patients with MRI documented failures, the tumor volumes obtained using the different sequences were compared with the recurrent gross tumor volume (rGTV).
  • Fractional component analysis showed that the intersection of the tumor volumes as defined on both T2 and FLAIR defined the majority of the union volume contributing 63.6% to the CTV union and 82.1% to the PTV union.
  • CONCLUSIONS: Although both T2 and FLAIR MRI sequences are used to define high grade glial neoplasm and surrounding edema, our results show that the volumes generated using these techniques are different and not interchangeable.
  • These differences have bearing on the use of intensity modulated radiation therapy (IMRT) and highly conformal treatment as well as on future clinical trials where the bias of using one technique over the other may influence the study outcome.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):517-26 [10802381.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2563-9 [16735709.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):915-28 [11429219.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1635-42 [11896114.001]
  • [Cites] Neurol India. 2003 Dec;51(4):512-7 [14742935.001]
  • [Cites] Radiology. 1971 Oct;101(1):201-2 [4106953.001]
  • [Cites] Proc Natl Cancer Conf. 1972;7:823-6 [4764939.001]
  • [Cites] AJR Am J Roentgenol. 1976 Feb;126(2):279-92 [175698.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1976 Jul-Aug;1(7-8):627-37 [185169.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] Neurology. 1980 Sep;30(9):907-11 [6252514.001]
  • [Cites] J Comput Assist Tomogr. 1985 Jul-Aug;9(4):659-75 [2991345.001]
  • [Cites] J Neurosurg. 1987 Jun;66(6):865-74 [3033172.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1405-9 [2542195.001]
  • [Cites] Acta Radiol. 1989 May-Jun;30(3):225-32 [2660886.001]
  • [Cites] J Neurosurg. 1989 Jul;71(1):1-9 [2661738.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1347-50 [2557310.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):395-8 [2154421.001]
  • [Cites] Radiother Oncol. 1991 Feb;20(2):99-110 [1851573.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(4):767-75 [1429103.001]
  • [Cites] Radiother Oncol. 1992 Oct;25(2):121-33 [1332134.001]
  • [Cites] AJNR Am J Neuroradiol. 1992 Nov-Dec;13(6):1555-64 [1332459.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Radiother Oncol. 1994 Feb;30(2):146-9 [8184112.001]
  • [Cites] Radiology. 1995 Mar;194(3):657-60 [7862959.001]
  • [Cites] Br J Radiol. 1963 Sep;36:645-9 [14066157.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Radiology. 2000 Nov;217(2):309-18 [11058623.001]
  • (PMID = 20109218.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2827477
  •  go-up   go-down


12. Li DR, Ishikawa T, Zhao D, Michiue T, Quan L, Zhu BL, Maeda H: Unexpected sudden death due to intracranial chordoma: an autopsy case. Forensic Sci Int; 2010 Jul 15;200(1-3):e15-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The brain was markedly swollen, with enlarged lateral and third ventricles, but the aqueduct was compressed and narrowed.
  • The brainstem is one of the most vulnerable regions in the brain, and careful examination of this region is important for forensic pathologists.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Chordoma / pathology. Death, Sudden / etiology
  • [MeSH-minor] Adult. Brain / pathology. Forensic Pathology. Humans. Hydrocephalus / etiology. Male. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Chordoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20444561.001).
  • [ISSN] 1872-6283
  • [Journal-full-title] Forensic science international
  • [ISO-abbreviation] Forensic Sci. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


13. Chaichana KL, McGirt MJ, Niranjan A, Olivi A, Burger PC, Quinones-Hinojosa A: Prognostic significance of contrast-enhancing low-grade gliomas in adults and a review of the literature. Neurol Res; 2009 Nov;31(9):931-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of contrast-enhancing low-grade gliomas in adults and a review of the literature.
  • OBJECTIVES: Survival and tumor recurrence for patients with low-grade gliomas is heterogeneous, with reported survival and recurrence times varying by several months to years.
  • METHODS: We retrospectively reviewed all adult patients who underwent a craniotomy for a hemispheric low-grade glioma (WHO grade II) from 1996 to 2006 at a single institution.
  • RESULTS: One hundred eighty-nine patients (87 fibrillary astrocytomas, 89 oligodendrogliomas and 13 mixed gliomas) were available for analysis, with 64 (34%) and 125 (66%) contrast-enhancing and non-enhancing tumors, respectively.
  • [MeSH-major] Brain Neoplasms / pathology. Contrast Media. Glioma / pathology. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Astrocytoma / epidemiology. Astrocytoma / pathology. Craniotomy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local. Oligodendroglioma / epidemiology. Oligodendroglioma / pathology. Predictive Value of Tests. Prognosis. Retrospective Studies. Sensitivity and Specificity. Severity of Illness Index. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19215664.001).
  • [ISSN] 1743-1328
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


14. Kao CL, Chiou SH, Ho DM, Chen YJ, Liu RS, Lo CW, Tsai FT, Lin CH, Ku HH, Yu SM, Wong TT: Elevation of plasma and cerebrospinal fluid osteopontin levels in patients with atypical teratoid/rhabdoid tumor. Am J Clin Pathol; 2005 Feb;123(2):297-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevation of plasma and cerebrospinal fluid osteopontin levels in patients with atypical teratoid/rhabdoid tumor.
  • Osteopontin, a cancer metastasis-associated gene, is specifically up-regulated in central nervous system (CNS) atypical teratoid/rhabdoid tumor (AT/RT), but its biological behavior in the progression of CNS AT/RT has never been studied.
  • We obtained plasma, cerebrospinal fluid (CSF), and brain tissue specimens from lobectomy or hemispherectomy samples from 39 patients (medulloblastoma, 16; AT/RT, 8; epilepsy, 6; hydrocephalus, 9).
  • The differences in osteopontin expression in plasma, CSF, and tumor samples in AT/RT and medulloblastoma correlated with survival differences.
  • [MeSH-major] Brain Neoplasms / metabolism. Rhabdoid Tumor / metabolism. Sialoglycoproteins. Teratoma / metabolism
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Enzyme-Linked Immunosorbent Assay. Humans. Infant. Infant, Newborn. Medulloblastoma / metabolism. Medulloblastoma / mortality. Medulloblastoma / pathology. Neoplasm Recurrence, Local. Osteopontin. Survival Rate

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842057.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 106441-73-0 / Osteopontin
  •  go-up   go-down


15. Francesconi AB, Dupre S, Matos M, Martin D, Hughes BG, Wyld DK, Lickliter JD: Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. J Clin Neurosci; 2010 Aug;17(8):970-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Glioblastoma / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Carboplatin / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20541421.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


16. Lourenço SV, A MS, Sotto MN, Bologna SB, Giacomo TB, Buim ME, Coutinho-Camillo CM, Silva SD, Landman G, Soares FA, Simonsen Nico MM: Primary oral mucosal melanoma: a series of 35 new cases from South America. Am J Dermatopathol; 2009 Jun;31(4):323-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Due to the rarity of this entity, data on epidemiology, tumor behavior, treatment, follow-up, and survival of patients are mainly based on single case reports.
  • The authors retrospectively studied 35 patients with primary melanoma of the oral cavity to report their clinical and pathological features, such as age, sex, site of the tumor, metastasis, treatment, response to therapy, and outcome.
  • [MeSH-major] Melanoma / epidemiology. Melanoma / secondary. Mouth Mucosa / pathology. Mouth Neoplasms / epidemiology. Mouth Neoplasms / pathology
  • [MeSH-minor] Adult. Aged, 80 and over. Bolivia / epidemiology. Bone Neoplasms / epidemiology. Bone Neoplasms / secondary. Brain Neoplasms / epidemiology. Brain Neoplasms / secondary. Brazil / epidemiology. Child. Female. Humans. Liver Neoplasms / epidemiology. Liver Neoplasms / secondary. Lung Neoplasms / epidemiology. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19461235.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


17. Timonen M, Kankaanranta L, Lundbom N, Collan J, Kangasmäki A, Kortesniemi M, Häkkinen AM, Lönngren A, Karjalainen S, Rasilainen M, Leinonen J, Huitti T, Jääskeläinen J, Kouri M, Savolainen S, Heikkinen S: 1H MRS studies in the Finnish boron neutron capture therapy project: detection of 10B-carrier, L-p-boronophenylalanine-fructose. Eur J Radiol; 2005 Nov;56(2):154-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Aged. Boron / therapeutic use. Brain Neoplasms / pathology. Brain Neoplasms / radiotherapy. Carcinoma / pathology. Carcinoma / radiotherapy. Female. Finland. Glioblastoma / pathology. Glioblastoma / radiotherapy. Humans. Hydrogen. Isotopes / therapeutic use. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / radiotherapy. Phantoms, Imaging. Plasma. Radiopharmaceuticals / therapeutic use

  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • Hazardous Substances Data Bank. HYDROGEN .
  • Hazardous Substances Data Bank. BORON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16233888.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / 4-boronophenylalanine-fructose; 0 / Boron Compounds; 0 / Isotopes; 0 / Radiopharmaceuticals; 30237-26-4 / Fructose; 7YNJ3PO35Z / Hydrogen; N9E3X5056Q / Boron
  •  go-up   go-down


18. Tamura K, Aoyagi M, Wakimoto H, Ando N, Nariai T, Yamamoto M, Ohno K: Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation. J Neurosurg; 2010 Aug;113(2):310-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serial MR and L-[methyl-(11)C] methionine PET images were employed to assess remnant or recurrent tumors after GKS.
  • Histopathological examination after GKS and EBRT showed variable mixtures of viable tumor tissues and necrosis.
  • Viable tumor tissues exhibited high MIB-1 indices but reduced numbers of tumor blood vessels.
  • There was marked accumulation of CD133-positive glioma cells, particularly in remnant tumors within the necrotic areas, in sections obtained after GKS plus EBRT, whereas CD133-positive cells appeared very infrequently in primary sections prior to adjuvant treatment.
  • CONCLUSIONS: The results indicate that CD133-positive glioma stemlike cells can survive high-dose irradiation, leading to recurrence, despite prolonged damage to tumor blood vessels.
  • [MeSH-major] Antigens, CD / metabolism. Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Glioblastoma / radiotherapy. Glioblastoma / surgery. Glycoproteins / metabolism. Peptides / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers / metabolism. Biopsy. Blood Vessels / radiation effects. Combined Modality Therapy. Disease Progression. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Positron-Emission Tomography. Radiation Tolerance. Radiosurgery. Radiotherapy. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205512.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers; 0 / Glycoproteins; 0 / Peptides
  •  go-up   go-down


19. Martino J, Taillandier L, Moritz-Gasser S, Gatignol P, Duffau H: Re-operation is a safe and effective therapeutic strategy in recurrent WHO grade II gliomas within eloquent areas. Acta Neurochir (Wien); 2009 May;151(5):427-36; discussion 436
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Brain Neoplasms / surgery. Glioma / surgery. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Biopsy. Brain Mapping. Chemotherapy, Adjuvant. Epilepsy / etiology. Epilepsy / prevention & control. Female. Humans. Male. Middle Aged. Monitoring, Intraoperative. Postoperative Care. Prognosis. Radiotherapy, Adjuvant. Reoperation

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19337688.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Austria
  •  go-up   go-down


20. Jung HY, Whang YM, Sung JS, Shin HD, Park BL, Kim JS, Shin SW, Seo HY, Seo JH, Kim YH: Association study of TP53 polymorphisms with lung cancer in a Korean population. J Hum Genet; 2008;53(6):508-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor suppressor gene, TP53, is located on chromosome 17p13.1 and is critical for DNA repair, cell-cycle control, and apoptosis.
  • [MeSH-major] Genes, p53. Lung Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Alleles. Base Sequence. Case-Control Studies. DNA, Neoplasm / genetics. Female. Haplotypes. Humans. Korea. Male. Middle Aged. Polymorphism, Single Nucleotide

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • Nature Publishing Group. Nature Publishing Group (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18363031.001).
  • [ISSN] 1434-5161
  • [Journal-full-title] Journal of human genetics
  • [ISO-abbreviation] J. Hum. Genet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


21. Shaw EJ, Haylock B, Husband D, du Plessis D, Sibson DR, Warnke PC, Walker C: Gene expression in oligodendroglial tumors. Anal Cell Pathol (Amst); 2010;33(2):81-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression in oligodendroglial tumors.
  • BACKGROUND: Oligodendroglial tumors with 1p/19q loss are more likely to be chemosensitive and have longer survival than those with intact 1p/19q, but not all respond to chemotherapy, warranting investigation of the biological basis of chemosensitivity.
  • METHODS: Gene expression profiling was performed using amplified antisense RNA from 28 oligodendroglial tumors treated with chemotherapy (26 serial stereotactic biopsy, 2 resection).
  • RESULTS: Unsupervised hierarchical clustering showed clustering of multiple samples from the same case in 14/17 cases and identified subgroups associated with tumor grade and 1p/19q status.
  • IQGAP1, INA, TGIF1, NR2F2 and MYCBP were differentially expressed in oligodendroglial tumors with 1p/19q loss.
  • CONCLUSION: Gene expression profiling using serial stereotactic biopsies indicated greater homogeneity within tumors than between tumors.
  • Genes associated with 1p/19q status or response were identified warranting further elucidation of their role in oligodendroglial tumors.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Aged. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Cluster Analysis. Drug Resistance, Neoplasm / genetics. Female. Gene Expression. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Principal Component Analysis. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cell Oncol (Dordr). 2011 Aug;34(4):407-8
  • (PMID = 20966545.001).
  • [ISSN] 2210-7185
  • [Journal-full-title] Analytical cellular pathology (Amsterdam)
  • [ISO-abbreviation] Anal Cell Pathol (Amst)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC4605574
  •  go-up   go-down


22. Balzarotti M, Fontana F, Marras C, Boiardi A, Croci D, Ciusani E, Salmaggi A: In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas. Oncol Res; 2006;16(5):245-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the last years results of preclinical and clinical studies have suggested that LMWH may be able to inhibit cell growth, cell invasion, and angiogenesis, which are key mechanisms involved in tumor progression, possibly influencing favorable clinical outcome in at least a proportion of cancer patients.
  • A significant decrease in tumor cell growth was observed after treatment with 10 U/ml (-21%; p = 0.001) and 100 U/ml (-26%; p < 0.001); tumor cells from AA (grade III;.
  • In conclusion, our results confirm the antineoplastic effect of LMWH, suggesting a potential direct role on tumor cell growth in high grade gliomas.
  • [MeSH-major] Brain Neoplasms / drug therapy. Cell Proliferation / drug effects. Enoxaparin / pharmacology. Glioma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Apoptosis / drug effects. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Female. Flow Cytometry. Gene Expression Regulation, Neoplastic / drug effects. Gene Expression Regulation, Neoplastic / genetics. Humans. Male. Middle Aged. Molecular Weight. Neoplasm Invasiveness. Receptor, PAR-1 / biosynthesis. Receptor, PAR-1 / drug effects. Receptor, PAR-1 / genetics. Sensitivity and Specificity. Structure-Activity Relationship. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17294805.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enoxaparin; 0 / Receptor, PAR-1
  •  go-up   go-down


23. Plans G, Brell M, Cabiol J, Villà S, Torres A, Acebes JJ: Intracranial retrograde dissemination in filum terminale myxopapillary ependymomas. Acta Neurochir (Wien); 2006 Mar;148(3):343-6; discussion 346
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Brain Neoplasms / secondary. Cauda Equina / pathology. Ependymoma / secondary. Meningeal Neoplasms / secondary. Neoplasm Metastasis / physiopathology. Spinal Cord Neoplasms / pathology. Subarachnoid Space / physiopathology
  • [MeSH-minor] Adult. Decompression, Surgical. Disease Progression. Headache / diagnosis. Headache / etiology. Headache / physiopathology. Humans. Hypothalamic Neoplasms / radiotherapy. Hypothalamic Neoplasms / secondary. Hypothalamus / pathology. Hypothalamus / physiopathology. Hypothalamus / surgery. Laminectomy. Low Back Pain / etiology. Low Back Pain / physiopathology. Low Back Pain / surgery. Lumbar Vertebrae / surgery. Magnetic Resonance Imaging. Male. Pituitary Gland, Posterior / pathology. Pituitary Gland, Posterior / physiopathology. Pituitary Gland, Posterior / surgery. Radiotherapy / methods. Third Ventricle / pathology. Third Ventricle / physiopathology. Third Ventricle / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16362177.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 35
  •  go-up   go-down


24. Schwarzmaier HJ, Eickmeyer F, von Tempelhoff W, Fiedler VU, Niehoff H, Ulrich SD, Yang Q, Ulrich F: MR-guided laser-induced interstitial thermotherapy of recurrent glioblastoma multiforme: preliminary results in 16 patients. Eur J Radiol; 2006 Aug;59(2):208-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The concept underlying the intervention is the cytoreduction of the tumor tissue by local thermocoagulation.
  • [MeSH-major] Brain Neoplasms / surgery. Glioblastoma / surgery. Laser Coagulation. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / surgery. Temperature
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / administration & dosage. Combined Modality Therapy. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Disease-Free Survival. Feasibility Studies. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16854549.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


25. Narayana A, Kelly P, Golfinos J, Parker E, Johnson G, Knopp E, Zagzag D, Fischer I, Raza S, Medabalmi P, Eagan P, Gruber ML: Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg; 2009 Jan;110(1):173-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A possible change in the invasiveness of the tumor following therapy is worrisome and must be closely monitored.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. Neovascularization, Pathologic / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Disease Progression. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Patient Compliance. Prospective Studies. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18834263.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


26. Yoo H, Baia GS, Smith JS, McDermott MW, Bollen AW, Vandenberg SR, Lamborn KR, Lal A: Expression of the hypoxia marker carbonic anhydrase 9 is associated with anaplastic phenotypes in meningiomas. Clin Cancer Res; 2007 Jan 1;13(1):68-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Hypoxia in the tumor microenvironment triggers a variety of genetic and adaptive responses that regulate tumor growth.
  • Tumor hypoxia is often associated with more malignant phenotypes, resistance to therapy, and poor survival.
  • The purpose of this study was to evaluate the prevalence of hypoxia in meningiomas using the endogenous hypoxia marker carbonic anhydrase 9 (CA9) and to relate the expression of CA9 to tumor vascularity, histopathologic grade, and clinical variables, such as recurrent tumor status.
  • In contrast, vascularity, as assessed by the percentage of vascular hotspots, was inversely associated with tumor grade (P = 0.023) and was not associated with CA9 expression.
  • Among lower-grade meningiomas, CA9 expression tended to be more common in recurrent tumors.
  • CONCLUSIONS: Tumor hypoxia is an endogenous feature of meningiomas, and therapeutic regimens should include strategies to target the subpopulation of hypoxic as well as the normoxic cells within the tumor.
  • [MeSH-major] Anoxia. Antigens, Neoplasm / biosynthesis. Carbonic Anhydrases / biosynthesis. Meningioma / drug therapy. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD34 / biosynthesis. Antineoplastic Agents / pharmacology. Female. Humans. Immunohistochemistry. Male. Microcirculation. Middle Aged. Phenotype. Time Factors. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17200340.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


27. Tabori U, Sung L, Hukin J, Laperriere N, Crooks B, Carret AS, Silva M, Odame I, Mpofu C, Strother D, Wilson B, Samson Y, Bouffet E, Canadian Pediatric Brain Tumor Consortium: Distinctive clinical course and pattern of relapse in adolescents with medulloblastoma. Int J Radiat Oncol Biol Phys; 2006 Feb 1;64(2):402-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Cerebellar Neoplasms / mortality. Medulloblastoma / mortality. Neoplasm Recurrence, Local / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Analysis of Variance. Child. Disease-Free Survival. Female. Humans. Male. Prognosis. Recurrence. Retrospective Studies. Sex Factors

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16198067.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


28. Okamoto H, Li J, Gläsker S, Vortmeyer AO, Jaffe H, Robison RA, Bogler O, Mikkelsen T, Lubensky IA, Oldfield EH, Zhuang Z: Proteomic comparison of oligodendrogliomas with and without 1pLOH. Cancer Biol Ther; 2007 Mar;6(3):391-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Chemoresistance is a widespread therapeutic challenge in glial tumors.
  • The molecular basis of chemoresistance is poorly understood, precluding advances in glioma treatment and leaving gliomas among the most lethal tumors.
  • Despite a high morphological similarity, tumors with allelic loss on the short arm of chromosome 1 (1pLOH) are more chemosensitive than those without 1pLOH.
  • Two of these proteins (glyoxalase I and Rho GDP dissociation inhibitor) have previously been shown to enhance chemoresistance in other tumors.
  • In turn, we identified twelve overexpressed proteins in tumors with 1pLOH that have previously been reported to induce chemosensitivity in other forms of human neoplasia.
  • [MeSH-major] Brain Neoplasms / metabolism. Chromosomes, Human, Pair 1 / genetics. Drug Resistance, Neoplasm / genetics. Loss of Heterozygosity. Neoplasm Proteins / analysis. Oligodendroglioma / metabolism. Proteome / genetics
  • [MeSH-minor] Adult. Aged. Blotting, Western. Electrophoresis, Gel, Two-Dimensional. Female. Humans. Male. Middle Aged. Proteomics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17264672.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA095809-04; United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Proteome
  •  go-up   go-down


29. Nakamura M, Ishida E, Shimada K, Kishi M, Nakase H, Sakaki T, Konishi N: Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas. Lab Invest; 2005 Feb;85(2):165-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Frequent allelic losses on the long arm of chromosome 22 (22q) in gliomas indicate the presence of tumor suppressor gene (TSG) at this location.
  • However, the target gene(s) residing in this chromosome are still unknown and their putative roles in the development of astrocytic tumors, especially in secondary glioblastoma, have not yet been defined.
  • To compile a precise physical map for the region of common deletions in astrocytic tumors, we performed a high-density loss of heterozygosity (LOH) analysis using 31 polymorphic microsatellite markers spanning 22q in a series of grade II diffuse astrocytomas, anaplastic astrocytomas, primary glioblastomas, and secondary glioblastomas that had evolved from lower grade astrocytomas.
  • In addition, the possibility of other putative TSGs on 22q12.3-13.2 and 22q13.31 that may also be involved in the development of primary glioblastomas cannot be ruled out.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 22. Glioblastoma / genetics. Loss of Heterozygosity. Tissue Inhibitor of Metalloproteinase-3 / genetics
  • [MeSH-minor] Adult. Alleles. DNA Methylation. Disease Progression. Epigenesis, Genetic. Gene Deletion. Gene Expression Regulation, Neoplastic. Genetic Markers. Humans. Immunohistochemistry. Microsatellite Repeats. Neoplasm Metastasis. Neoplasm Staging. Physical Chromosome Mapping. Polymorphism, Genetic. Prognosis. Promoter Regions, Genetic. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15592495.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / Tissue Inhibitor of Metalloproteinase-3
  •  go-up   go-down


30. Pfister C, Ritz R, Endemann E, Schittenhelm J, Bornemann A, Tatagiba MS, Roser F: Evidence of ubiquitous in vivo and in vitro expression of pro-apoptotic Smac/DIABLO protein in meningioma cell lines. Oncol Rep; 2009 May;21(5):1181-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although meningiomas are one of the most common tumors in the central nervous system, the adjuvant treatment for recurrent or malignant meningiomas is not satisfactory.
  • Changes in apoptosis mechanisms play important roles in tumor pathogenesis.
  • Constant high-level Smac/DIABLO respectively low-level survivin expression in meningiomas and normal brain demonstrate similar apoptotic behavior of meningiomas compared to normal brain tissue.
  • These findings indicate no pathological overexpression of survivin in meningiomas as is evident in several other cancer types impeding apoptosis.
  • [MeSH-major] Meningeal Neoplasms / metabolism. Meningioma / metabolism. Mitochondrial Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Intracellular Signaling Peptides and Proteins / genetics. Male. Middle Aged. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics. Tumor Cells, Cultured. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19360292.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DIABLO protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Mitochondrial Proteins; 0 / RNA, Neoplasm
  •  go-up   go-down


31. Tangjitgamol S, Manusirivithaya S, Choomchuay N, Leelahakorn S, Thawaramara T, Pataradool K, Suekwatana P: Paclitaxel and carboplatin for large cell neuroendocrine carcinoma of the uterine cervix. J Obstet Gynaecol Res; 2007 Apr;33(2):218-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, she subsequently had progressive diseases in the liver and brain and finally died at 44 months after primary diagnosis and 19 months after recurrent diseases.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Carcinoma, Large Cell / drug therapy. Carcinoma, Neuroendocrine / drug therapy. Paclitaxel / therapeutic use. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents, Phytogenic / therapeutic use. Brain Neoplasms / secondary. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Fatal Outcome. Female. Humans. Liver Neoplasms / secondary. Neoplasm Recurrence, Local. Ovariectomy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17441901.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


32. Sarissky M, Lavicka J, Kocanová S, Sulla I, Mirossay A, Miskovsky P, Gajdos M, Mojzis J, Mirossay L: Diazepam enhances hypericin-induced photocytotoxicity and apoptosis in human glioblastoma cells. Neoplasma; 2005;52(4):352-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme (GBM) is neoplasm which is resistant to all currently used treatment modalities including surgery, radiation therapy and chemotherapy.
  • For the study, we used U-87 MG and U373 MG glioma cell lines and primary cultures of GBM cells prepared from peroperatively obtained tumor specimens.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Brain Neoplasms / pathology. Diazepam / pharmacology. GABA Modulators / pharmacology. Glioblastoma / pathology. Perylene / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Drug Interactions. Female. Flow Cytometry. Humans. Male. Middle Aged. Photochemotherapy. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. PERYLENE .
  • Hazardous Substances Data Bank. DIAZEPAM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16059654.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / GABA Modulators; 5QD5427UN7 / Perylene; 7V2F1075HD / hypericin; Q3JTX2Q7TU / Diazepam
  •  go-up   go-down


33. Abe T, Kamida T, Goda M, Inoue R, Fujiki M, Kobayashi H, Hatano Y, Shibuya H, Fujiwara S, Terashi H, Mori T: Intracranial infiltration by recurrent scalp dermatofibrosarcoma protuberans. J Clin Neurosci; 2009 Oct;16(10):1358-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histological findings demonstrated a DFSP that both abutted and occasionally invaded the adjacent brain cortex, while extending along the Virchow-Robin spaces.
  • [MeSH-major] Dermatofibrosarcoma / surgery. Neoplasm Recurrence, Local / surgery. Scalp / pathology. Skin Neoplasms / surgery
  • [MeSH-minor] Humans. Magnetic Resonance Imaging. Male. Radiosurgery / methods. Young Adult

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19560926.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


34. Adam Y, Benezech J, Blanquet A, Fuentes JM, Bousigue JY, Debono B, Duplessis E, Espagno C, Plas JY, Lescure JP, Destandau J, Hladky JP, Grunewald P, Mahla K, Remond J, Louis E: [Intramedullary tumors. Results of a national investigation in private neurosurgery]. Neurochirurgie; 2010 Aug;56(4):344-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intramedullary tumors. Results of a national investigation in private neurosurgery].
  • The frequency of intramedullary tumors is 0.5 cases per year for 100,000 inhabitants.
  • Tumor removal was complete in the cases of ependymoma and hemangioblastoma and subtotal in the cases of astrocytoma.
  • Diagnostic delay: malignant tumors, one to nine months; low grades; three to six years (range, eight months to 25 years).
  • CONCLUSION: Total removal of the intramedullary tumors is a challenge.
  • [MeSH-major] Brain Stem Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Delayed Diagnosis. Female. Follow-Up Studies. France / epidemiology. Humans. Magnetic Resonance Imaging. Male. Microsurgery. Middle Aged. Neoplasm Recurrence, Local. Neurosurgical Procedures. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20097390.001).
  • [ISSN] 1773-0619
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


35. Sade B, Lee JH: High incidence of optic canal involvement in clinoidal meningiomas: rationale for aggressive skull base approach. Acta Neurochir (Wien); 2008 Nov;150(11):1127-32; discussion 1132
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we aimed to document the incidence of optic canal involvement (OCI) by the tumor, its management using a skull base technique, and its significance with relation to the visual outcome.
  • With the use of the skull base technique, without which the tumor in the optic canal could not have been removed completely and safely, visual improvement of 77% and stability of 23% was achieved.
  • [MeSH-major] Meningeal Neoplasms / epidemiology. Meningioma / epidemiology. Neoplasm Invasiveness / pathology. Optic Nerve / pathology. Sphenoid Bone / pathology. Vision Disorders / epidemiology
  • [MeSH-minor] Adult. Aged. Comorbidity. Cranial Fossa, Anterior / anatomy & histology. Cranial Fossa, Anterior / pathology. Cranial Fossa, Anterior / surgery. Disease Progression. Female. Humans. Incidence. Magnetic Resonance Imaging. Male. Middle Aged. Neurosurgical Procedures / methods. Preoperative Care. Recovery of Function / physiology. Retrospective Studies. Skull Base Neoplasms / epidemiology. Skull Base Neoplasms / pathology. Skull Base Neoplasms / surgery. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18936874.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


36. Mawrin C, Schneider T, Firsching R, Wiedemann FR, Dietzmann K, Bornemann A, Romeike BF, Sellhaus B, von Deimling A: Assessment of tumor cell invasion factors in gliomatosis cerebri. J Neurooncol; 2005 Jun;73(2):109-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of tumor cell invasion factors in gliomatosis cerebri.
  • Gliomatosis cerebri (GC) is a rare brain tumor characterized by widespread infiltration of large parts of the brain and sometimes even the spinal cord.
  • To determine the cause of this extraordinary degree of brain invasion, we studied immunoexpression of factors associated with brain infiltration in low-grade and high-grade tumor samples from nine GC cases.
  • We further determined the allelic status of the fibroblastic growth factor receptor 4 (FGFR4) gene at position 388 (arginine [Arg(388)] or glycine [Gly(388)]) in eighteen GC patients, because the presence of at least one Arg(388) allele has been suggested to favor tumor cell motility compared to tumor cells homozygeous for the Gly(388) allele.
  • Immunohistochemical analyses showed that tumor samples from three GC cases expressed Tenascin-C, whereas six cases had CD44 - immunopositive tumor samples.
  • In tumor-free control DNA, the Arg(388) phenotype was present in 60%.
  • These data indicate that CD44 expression might be related to the tumor infiltration in GC, and that patients suffering from GC or other common astrocytomas do not have a significantly increased frequency of the tumor cell motility-favoring Arg(388) FGFR4 allele.
  • [MeSH-major] Antigens, CD44 / metabolism. Brain Neoplasms / pathology. Neoplasms, Neuroepithelial / pathology. Receptors, Fibroblast Growth Factor / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Alleles. Arginine / genetics. Female. Humans. Immunohistochemistry. Male. Matrix Metalloproteinase 9 / metabolism. Middle Aged. Neoplasm Invasiveness. Receptor, Fibroblast Growth Factor, Type 4. Severity of Illness Index. Tenascin / metabolism

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2005 Apr;72 (2):115-22 [15925990.001]
  • [Cites] J Neurosurg. 1995 May;82(5):858-63 [7536236.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Sep;61(9):806-14 [12230327.001]
  • [Cites] Br J Cancer. 1999 Apr;79(11-12):1828-35 [10206300.001]
  • [Cites] Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):495-502 [10571411.001]
  • [Cites] Cancer Res. 1994 Aug 1;54(15):3988-92 [7518347.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Oct 20;251(2):632-6 [9792825.001]
  • [Cites] Hum Pathol. 1995 Oct;26(10):1144-7 [7557949.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):298-307 [7616276.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):840-7 [11830541.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2894-901 [12231534.001]
  • [Cites] Neurosurgery. 1995 Aug;37(2):294-301; discussion 301-2 [7477782.001]
  • [Cites] Mod Pathol. 1997 Dec;10(12):1239-46 [9436970.001]
  • [Cites] Br J Neurosurg. 1991;5(2):187-93 [1650563.001]
  • [Cites] Clin Neuropathol. 1999 Jul-Aug;18(4):190-7 [10442461.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2A):945-9 [9137432.001]
  • [Cites] J Neurooncol. 2001 Oct;55(1):11-7 [11804278.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6851-5 [11156378.001]
  • [Cites] Pathol Oncol Res. 2000;6(2):118-24 [10936787.001]
  • [Cites] Ann Neurol. 2002 Oct;52(4):390-9 [12325066.001]
  • [Cites] Clin Neuropathol. 1985 Jul-Aug;4(4):135-48 [4053456.001]
  • [Cites] Acta Neuropathol. 2003 Jun;105(6):529-36 [12734658.001]
  • [Cites] Trends Biochem Sci. 1998 Feb;23(2):59-62 [9538690.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):182-9 [8548761.001]
  • [Cites] Cancer Res. 1983 Jun;43(6):2796-805 [6342760.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):484-8 [8290551.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):429-37 [9708803.001]
  • [Cites] Brain Tumor Pathol. 1998;15(2):111-6 [10328549.001]
  • [Cites] Neurol Res. 2002 Apr;24(3):244-8 [11958417.001]
  • [Cites] Exp Cell Res. 1992 Nov;203(1):80-90 [1426053.001]
  • [Cites] Hum Pathol. 2003 Jan;34(1):102-6 [12605375.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):44-51 [11550301.001]
  • [Cites] J Neurooncol. 2001 May;52(3):237-40 [11519853.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2430-9 [14635078.001]
  • [Cites] Int J Cancer. 1992 Feb 20;50(4):572-7 [1537623.001]
  • (PMID = 15981099.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Receptors, Fibroblast Growth Factor; 0 / Tenascin; 94ZLA3W45F / Arginine; EC 2.7.10.1 / FGFR4 protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 4; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


37. Kim HS, Kim JH, Kim SH, Cho KG, Kim SY: Posttreatment high-grade glioma: usefulness of peak height position with semiquantitative MR perfusion histogram analysis in an entire contrast-enhanced lesion for predicting volume fraction of recurrence. Radiology; 2010 Sep;256(3):906-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty-nine patients with pathologically proved predominant tumor recurrence (tumor recurrence group, tumor fraction > or =50% [n = 14]), mixed tumor and posttreatment change (mixed group, tumor fraction > or =20% and <50% [n = 10]), and predominant posttreatment change (treatment change group, tumor fraction <20% [n = 15]) were evaluated.
  • According to receiver operating characteristic curve analyses, PHP provided sensitivity of 90.2% and specificity of 91.1% for differentiating tumor recurrence from mixed and treatment change groups at an optimum threshold of 1.7 by using leave-one-out cross-validation.
  • MV helped distinguish treatment change group from tumor recurrence and mixed groups at an optimum threshold of 2.6 (sensitivity, 96.5%; specificity, 93.1%).
  • [MeSH-major] Brain Neoplasms / pathology. Glioma / pathology. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Cerebrovascular Circulation. Contrast Media. Female. Humans. Image Interpretation, Computer-Assisted. Logistic Models. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. ROC Curve. Retrospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2010.
  • (PMID = 20634429.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


38. Neyns B, Chaskis C, Joosens E, Menten J, D'Hondt L, Branle F, Sadones J, Michotte A: A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. Cancer Invest; 2008 Apr-May;26(3):269-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Cohort Studies. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Survival Analysis


39. Baehring JM, Androudi S, Longtine JJ, Betensky RA, Sklar J, Foster CS, Hochberg FH: Analysis of clonal immunoglobulin heavy chain rearrangements in ocular lymphoma. Cancer; 2005 Aug 1;104(3):591-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Eye Neoplasms / genetics. Gene Rearrangement. Immunoglobulin Heavy Chains / genetics. Lymphoma, Non-Hodgkin / genetics. Vitreous Body / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Chronic Disease. DNA, Neoplasm / genetics. Diagnosis, Differential. Female. Flow Cytometry. Genes, Immunoglobulin. Humans. Immunoglobulin Variable Region / genetics. Male. Middle Aged. Polymerase Chain Reaction. Retrospective Studies. Sensitivity and Specificity. Vitrectomy

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15973665.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region
  •  go-up   go-down


40. Hong S, Cho BC, Choi HJ, Jung M, Lee SH, Park KS, Kim SK, Kim JH: Prognostic factors in small cell lung cancer: a new prognostic index in Korean patients. Oncology; 2010;79(3-4):293-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patient history was reviewed regarding both clinical and tumor-related markers, and treatment-related factors were also evaluated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / mortality. Lung Neoplasms / mortality. Small Cell Lung Carcinoma / mortality. Survivors
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / metabolism. Bone Neoplasms / drug therapy. Bone Neoplasms / mortality. Bone Neoplasms / secondary. Brain Neoplasms / drug therapy. Brain Neoplasms / mortality. Brain Neoplasms / secondary. Female. Follow-Up Studies. Humans. Keratin-19 / metabolism. Liver Neoplasms / drug therapy. Liver Neoplasms / mortality. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Prognosis. Republic of Korea. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 S. Karger AG, Basel.
  • (PMID = 21412014.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Keratin-19; 0 / antigen CYFRA21.1
  •  go-up   go-down


41. Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Wong TZ, Bigner DD: Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med; 2008 Jan;49(1):30-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.
  • alpha-Particle-emitting radionuclides, such as (211)At, with a 7.2-h half-life, may be optimally suited for the molecularly targeted radiotherapy of strategically sensitive tumor sites, such as those in the central nervous system.
  • Because of the much shorter range and more potent cytotoxicity of alpha-particles than of beta-particles, (211)At-labeled agents may be ideal for the eradication of tumor cells remaining after surgical debulking of malignant brain tumors.
  • The main goal of this study was to investigate the feasibility and safety of this approach in patients with recurrent malignant brain tumors.
  • Specifically, the regional administration of (211)At-ch81C6 is feasible, safe, and associated with a promising antitumor benefit in patients with malignant central nervous system tumors.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunother. 1997 May;20(3):214-43 [9181460.001]
  • [Cites] Appl Radiat Isot. 1996 Feb;47(2):135-43 [8852627.001]
  • [Cites] Radiat Res. 1998 Feb;149(2):155-62 [9457895.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2202-12 [9626222.001]
  • [Cites] Nucl Med Biol. 1998 May;25(4):351-7 [9639296.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1933-40 [9731050.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2495-502 [9796983.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):491-9 [10487576.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:199S-204S [15653670.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):1042-51 [15937318.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4451-9 [15958630.001]
  • [Cites] J Nucl Med. 2005 Aug;46(8):1393-400 [16085599.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):115-22 [16382120.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):912-8 [16741299.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10 Suppl):3275s-3280s [10541375.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Curr Pharm Des. 2000 Sep;6(14):1433-55 [10903402.001]
  • [Cites] J Nucl Med. 2001 Oct;42(10):1508-15 [11585865.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1389-97 [11870184.001]
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):362-9 [11920587.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1233-9 [12149203.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1259-75 [12419456.001]
  • [Cites] Cancer Res. 1983 Jun;43(6):2796-805 [6342760.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Nov;13(11):1767-73 [3667382.001]
  • [Cites] Cancer Res. 1989 May 15;49(10):2807-13 [2469537.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(1):55-7 [1512163.001]
  • [Cites] Invest Radiol. 1993 Jun;28(6):488-96 [7686539.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] Nucl Med Biol. 1996 May;23(4):449-58 [8832699.001]
  • [Cites] Nucl Med Biol. 1997 Apr;24(3):255-61 [9228660.001]
  • (PMID = 18077533.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA108786; United States / NINDS NIH HHS / NS / NS20023; United States / NINDS NIH HHS / NS / P50 NS020023; United States / NCI NIH HHS / CA / R01 CA042324; United States / NINDS NIH HHS / NS / P50 NS020023-268624; United States / NCI NIH HHS / CA / CA014236-35S59008; United States / NCI NIH HHS / CA / CA108786; United States / NCI NIH HHS / CA / CA42324; United States / NCI NIH HHS / CA / CA11898; United States / NCRR NIH HHS / RR / M01 RR30; United States / NINDS NIH HHS / NS / NS020023-268624; United States / NCI NIH HHS / CA / R37 CA042324; United States / NCI NIH HHS / CA / P30 CA014236; United States / NCI NIH HHS / CA / R37 CA042324-23; United States / NCI NIH HHS / CA / P30 CA014236-35S59008; United States / NCI NIH HHS / CA / R37 CA011898
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Radioisotopes; 0 / Radiopharmaceuticals; 0 / Tenascin; XI595HAL7H / Astatine
  • [Other-IDs] NLM/ NIHMS180689; NLM/ PMC2832604
  •  go-up   go-down


42. Bozinov O, Kalk JM, Krayenbühl N, Woernle CM, Sure U, Bertalanffy H: Decreasing expression of the interleukin-13 receptor IL-13Ralpha2 in treated recurrent malignant gliomas. Neurol Med Chir (Tokyo); 2010;50(8):617-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This gene is highly expressed in various types of human tumors including malignant gliomas.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Glioblastoma / metabolism. Interleukin-13 Receptor alpha2 Subunit / metabolism. Neoplasm Recurrence, Local / metabolism
  • [MeSH-minor] Actins / genetics. Actins / metabolism. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Exotoxins / therapeutic use. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Immunotoxins / therapeutic use. Interleukin-13 / therapeutic use. Male. Middle Aged. Nimustine / administration & dosage. RNA / analysis. Teniposide / administration & dosage. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. TENIPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20805641.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Actins; 0 / Exotoxins; 0 / IL13-PE38QQR; 0 / Immunotoxins; 0 / Interleukin-13; 0 / Interleukin-13 Receptor alpha2 Subunit; 0S726V972K / Nimustine; 63231-63-0 / RNA; 957E6438QA / Teniposide
  •  go-up   go-down


43. Han JH, Park CK, Lee SH, Kim CY, Kim DW, Paek SH, Kim DG, Heo DS, Kim IH, Jung HW: Preradiation chemotherapy with ACNU-CDDP in patients with newly diagnosed glioblastoma: a retrospective analysis. Chemotherapy; 2009;55(3):145-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Preradiation chemotherapy using ACNU-CDDP was administered as an initial adjuvant therapy for 87 (57.6%) patients (ACNU-CDDP group), radiation therapy was performed in 31 (20.5%) patients (RT group) and the remaining 33 (21.9%) patients were treated with other regimens or refused to undergo further treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Cisplatin / therapeutic use. Glioblastoma / drug therapy. Nimustine / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Salvage Therapy. Survival Analysis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19390187.001).
  • [ISSN] 1421-9794
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0S726V972K / Nimustine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


44. Gerganov VM, Klinge PM, Nouri M, Stieglitz L, Samii M, Samii A: Prognostic clinical and radiological parameters for immediate facial nerve function following vestibular schwannoma surgery. Acta Neurochir (Wien); 2009 Jun;151(6):581-7; discussion 587
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Brain Stem / pathology. Brain Stem / surgery. Dissection / adverse effects. Dissection / methods. Dissection / standards. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neoplasm Invasiveness / diagnosis. Neoplasm Invasiveness / pathology. Petrous Bone / anatomy & histology. Petrous Bone / pathology. Petrous Bone / surgery. Predictive Value of Tests. Prognosis. Retrospective Studies. Severity of Illness Index

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19337682.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


45. Ikeda H: Mutational analysis of transforming growth factor-beta receptor type II and Smad3 tumor suppressor genes in prolactinomas. Brain Tumor Pathol; 2006 Apr;23(1):7-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutational analysis of transforming growth factor-beta receptor type II and Smad3 tumor suppressor genes in prolactinomas.
  • The presence of transforming growth factor-beta receptor type II and Smad3 gene abnormality was examined in human prolactinomas by single-strand conformation polymorphism screening for gene abnormality and band shift in tumor tissue and peripheral blood samples obtained from 14 patients treated for prolactinoma.
  • [MeSH-major] DNA Mutational Analysis. Pituitary Neoplasms / genetics. Prolactinoma / genetics. Protein-Serine-Threonine Kinases / genetics. Receptors, Transforming Growth Factor beta / genetics. Smad3 Protein / genetics
  • [MeSH-minor] Adult. DNA Primers. DNA, Neoplasm / genetics. Exons / genetics. Female. Human Growth Hormone / biosynthesis. Humans. Male. Middle Aged. Pituitary Gland / metabolism. Polymorphism, Single-Stranded Conformational / genetics. Prolactin / biosynthesis. Proto-Oncogene Proteins / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction / genetics. Signal Transduction / physiology

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095113.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / MEN1 protein, human; 0 / Proto-Oncogene Proteins; 0 / Receptors, Transforming Growth Factor beta; 0 / SMAD3 protein, human; 0 / Smad3 Protein; 12629-01-5 / Human Growth Hormone; 9002-62-4 / Prolactin; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down


46. Ogawa K, Yoshii Y, Shikama N, Nakamura K, Uno T, Onishi H, Itami J, Shioyama Y, Iraha S, Hyodo A, Toita T, Kakinohana Y, Tamaki W, Ito H, Murayama S: Spinal recurrence from intracranial germinoma: risk factors and treatment outcome for spinal recurrence. Int J Radiat Oncol Biol Phys; 2008 Dec 1;72(5):1347-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / radiotherapy. Germinoma / pathology. Germinoma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Spinal Cord Neoplasms / secondary. Spinal Neoplasms / secondary
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Chorionic Gonadotropin / blood. Female. Humans. Japan. Magnetic Resonance Imaging. Male. Radiotherapy Dosage. Recurrence. Retrospective Studies. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Germinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18513888.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  •  go-up   go-down


47. Muhonen MG, Bierman JS, Hussain NS, Hanley HA, Hussain SS: Giant intracranial teratoma and lack of cortical development in a fetus. Case report. J Neurosurg; 2005 Aug;103(2 Suppl):180-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antenatal diagnosis of an intracranial neoplasm is extremely rare.
  • As the tumor increased in size, near-complete brain atrophy ensued.
  • In cases in which abnormal brain development is suspected in a fetus, the use of fetal MR imaging can give a clearer picture of the pathological entity, which may allow for a more accurate diagnosis.
  • The usefulness of fetal MR imaging in monitoring brain development and tumor growth during treatment planning is discussed.
  • [MeSH-major] Brain Neoplasms / embryology. Cerebral Cortex / embryology. Fetal Diseases / physiopathology. Teratoma / embryology
  • [MeSH-minor] Adult. Atrophy. Brain / embryology. Brain / pathology. Female. Fetal Death. Fetal Development. Humans. Labor, Induced. Magnetic Resonance Imaging. Pregnancy. Pregnancy Trimester, First. Pregnancy Trimester, Second. Ultrasonography, Prenatal


48. Küpeli S, Hazirolan T, Varan A, Akata D, Alehan D, Hayran M, Besim A, Büyükpamukçu M: Evaluation of coronary artery disease by computed tomography angiography in patients treated for childhood Hodgkin's lymphoma. J Clin Oncol; 2010 Feb 20;28(6):1025-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CBC, lipid profile, urine analysis, brain natriuretic peptide, troponin-T, creatinine kinase-myocardial band, ECG, telecardiography, echocardiography, and CTA of the patients were performed.
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Child. Child, Preschool. Cohort Studies. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Radiotherapy / adverse effects. Survival Rate. Treatment Outcome. Young Adult


49. Yin XL, Ng HK: [Molecular genetic studies on ganglioglioma]. Zhonghua Bing Li Xue Za Zhi; 2005 Mar;34(3):147-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study the genetic alterations of ganglioglioma through the entire genome, and to investigate the pathogenesis of this neoplasm.
  • On the other hand, genetic imbalances were also involved in multiple chromosomes including 2q33-q34, 8q12-q22, 14q21-qter, 15q26-qter and Y.
  • CONCLUSION: Loss of genetic materials on chromosome 9p and gain on chromosome 7 may be associated with the pathogenesis of this neoplasm.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 7. Chromosomes, Human, Pair 9. Ganglioglioma / genetics
  • [MeSH-minor] Adolescent. Adult. Chromosome Deletion. Female. Follow-Up Studies. Humans. In Situ Hybridization, Fluorescence. Male. Nucleic Acid Hybridization. Receptor, Epidermal Growth Factor / metabolism

  • Genetic Alliance. consumer health - Ganglioglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15938824.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


50. Peca C, Pacelli R, Elefante A, Del Basso De Caro ML, Vergara P, Mariniello G, Giamundo A, Maiuri F: Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis? Clin Neurol Neurosurg; 2009 May;111(4):331-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: This study investigates the diagnosis and management of patients with resected brain glioblastomas who presented early clinical and neuroradiological worsening after the completion of the Stupp protocol.
  • METHODS: Fifty patients with brain glioblastoma treated by surgical resection and Stupp protocol were reviewed; 15 among them (30%) had early clinical and neuroradiological worsening at the 6-month follow-up.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Neoplasm Recurrence, Local / diagnosis. Radiation Injuries / diagnosis. Radiation Tolerance / drug effects
  • [MeSH-minor] Adult. Aged. Ataxia / etiology. Chemotherapy, Adjuvant. Confusion / etiology. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Magnetic Resonance Spectroscopy. Male. Middle Aged. Necrosis. Radiotherapy, Adjuvant. Reoperation. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19117668.001).
  • [ISSN] 1872-6968
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


51. Schmidt M, Simon T, Hero B, Eschner W, Dietlein M, Sudbrock F, Bongartz R, Berthold F, Schicha H: Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004. Nuklearmedizin; 2006;45(4):145-51; quiz N39-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] 3-Iodobenzylguanidine / therapeutic use. Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Iodine Radioisotopes / therapeutic use. Neuroblastoma / drug therapy. Neuroblastoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Follow-Up Studies. Humans. Neoplasm Staging. Regression Analysis. Retrospective Studies. Survival Analysis. Treatment Outcome


52. Shih HA, Betensky RA, Dorfman MV, Louis DN, Loeffler JS, Batchelor TT: Genetic analyses for predictors of radiation response in glioblastoma. Int J Radiat Oncol Biol Phys; 2005 Nov 1;63(3):704-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prior studies have suggested that underlying genetic alterations in the tumor may account for some of this treatment-related heterogeneity.
  • Moreover, no association was found between these endpoints and the other genetic alterations assayed (TP53 mutation, CDKN2A/p16 deletion, loss of heterozygosity 1p, loss of heterozygosity 10q, and loss of heterozygosity 19q).
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / radiotherapy. Glioblastoma / genetics. Glioblastoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 19 / genetics. Disease-Free Survival. Female. Gene Amplification. Gene Deletion. Genes, p16. Genes, p53 / genetics. Genetic Markers. Humans. Male. Middle Aged. Neoplasm Proteins / genetics. Receptor, Epidermal Growth Factor / genetics

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15978739.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA57683
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / Neoplasm Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


53. Abdullah JM, Farizan A, Asmarina K, Zainuddin N, Ghazali MM, Jaafar H, Isa MN, Naing NN: Association of loss of heterozygosity and PTEN gene abnormalities with paraclinical, clinical modalities and survival time of glioma patients in Malaysia. Asian J Surg; 2006 Oct;29(4):274-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of loss of heterozygosity and PTEN gene abnormalities with paraclinical, clinical modalities and survival time of glioma patients in Malaysia.
  • BACKGROUND: The pattern of allelic loss of heterozygosity (LOH) and PTEN mutations appear to be associated with the progression of gliomas leading to a decrement in the survival rate of patients.
  • This present study was carried out to determine the LOH and PTEN mutational status in glioma patients and its association with patients' survival.
  • METHODS: Thirty-seven Malaysian glioma patients of the Malay race were subject to PTEN mutational analysis and the presence of LOH using the cold single-strand conformation polymorphism method, and their clinical and paraclinical response were correlated.
  • RESULTS: Among analysed glioma patients, seven (21.6%) cases with PTEN mutations were detected and 12 (32.4%) of 37 patients showed presence of LOH.
  • Univariate analysis showed that tumour grade, vascularization, PTEN mutation, LOH and combination of both PTEN mutation and LOH were significantly associated with glioma patients' survival.
  • Multivariate analysis revealed that no factors contributed to survival time.
  • CONCLUSION: The results show that PTEN mutation and LOH are quite frequent in Malaysian glioma patients.
  • However, they have no impact on the survival outcome of patients.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17098662.001).
  • [ISSN] 1015-9584
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


54. Inoue T, Nishimura S, Hayashi N, Numagami Y, Midorikawa H, Shimamura N, Yajima N, Nishijima M: [Intracranial osteolytic hemangiopericytoma manifesting as a rapidly enlarging extracranial soft tissue mass lesion]. No Shinkei Geka; 2007 Mar;35(3):275-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hemangiopericytoma is a highly vascular and rapidly growing tumor, which tends to recur at distant locations.
  • Complete surgical resection is often difficult because of intraoperative excessive hemorrhage or brain swelling.
  • Angiography demonstrated obstruction of the superior sagittal sinus and dense tumor staining with slow circulation and venous drainage.
  • [MeSH-major] Hemangiopericytoma / surgery. Skin Neoplasms / pathology. Skull Neoplasms / surgery
  • [MeSH-minor] Adult. Diagnosis, Differential. Frontal Lobe / pathology. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Soft Tissue Neoplasms / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] No Shinkei Geka. 2007 Apr;35(4):412
  • (PMID = 17352153.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


55. Bisenkov LN, Gaĭdar BV, Shalaev SA, Parfenov VE, Vasilashko VI, Baranenko IuV: [Surgical treatment of lung cancer patients with brain metastases]. Vestn Khir Im I I Grek; 2005;164(1):76-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of lung cancer patients with brain metastases].
  • The authors present an experience with diagnosing and treatment of 16 patients suffering from lung cancer with solitary metastasis into the brain.
  • This solution was based on the detection of an extensive spread of lung cancer: multiple metastasis outside the thoracic cavity and the brain or inside the brain, and in one case--due to a considerable reduction of indices of the functional and reserve capacities of respiration and blood circulation.
  • Single-step operations were carried out in 9 patients with lung cancer with a solitary metastasis into the brain (resection of the lung with an ablation of the brain metastasis).
  • Two other patients operated upon in June 2003 and March 2004 are still alive and feel much better.
  • [MeSH-major] Adenocarcinoma / surgery. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Carcinoma, Small Cell / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Lung / pathology. Male. Middle Aged. Neoplasm Staging. Pneumonectomy. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15957816.001).
  • [ISSN] 0042-4625
  • [Journal-full-title] Vestnik khirurgii imeni I. I. Grekova
  • [ISO-abbreviation] Vestn. Khir. Im. I. I. Grek.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


56. Friebe A, Horn M, Schmidt F, Janssen G, Schmid-Wendtner MH, Volkenandt M, Hauschild A, Goldsmith CH, Schaefer M: Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma. Psychosomatics; 2010 Nov-Dec;51(6):466-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Depression / chemically induced. Immunologic Factors / adverse effects. Interferon-alpha / adverse effects. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Chi-Square Distribution. Dose-Response Relationship, Drug. Female. Humans. Longitudinal Studies. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Psychiatric Status Rating Scales

  • MedlinePlus Health Information. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21051677.001).
  • [ISSN] 1545-7206
  • [Journal-full-title] Psychosomatics
  • [ISO-abbreviation] Psychosomatics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / Interferon-alpha
  •  go-up   go-down


57. Vauleon E, Auger N, Benouaich-Amiel A, Laigle-Donadey F, Kaloshi G, Lejeune J, Delattre JY, Thillet J, Sanson M: The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma. Cancer Genet Cytogenet; 2007 Jan 1;172(1):33-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Brain Neoplasms / genetics. Epidermal Growth Factor / genetics. Glioblastoma / genetics. Polymorphism, Genetic / genetics
  • [MeSH-minor] 5' Untranslated Regions / genetics. Adult. Aged. Aged, 80 and over. Animals. CHO Cells. Case-Control Studies. Cricetinae. DNA, Neoplasm / genetics. Genetic Predisposition to Disease. Genotype. Humans. Middle Aged. Prognosis. Risk Factors. Survival Rate. Transfection

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175377.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5' Untranslated Regions; 0 / DNA, Neoplasm; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


58. Aboulafia DM, Ratner L, Miles SA, Harrington WJ Jr, AIDS Associated Malignancies Clinical Trials Consortium: Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019. Clin Lymphoma Myeloma; 2006 Mar;6(5):399-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: A consistent association with Epstein-Barr Virus (EBV) distinguishes acquired immunodeficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL) from that which occurs in the general population.
  • [MeSH-major] Antiretroviral Therapy, Highly Active / methods. Brain Neoplasms / drug therapy. Brain Neoplasms / mortality. Interleukins / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / mortality
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Positron-Emission Tomography. Prospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome


59. Theodosopoulos PV, Leach J, Kerr RG, Zimmer LA, Denny AM, Guthikonda B, Froelich S, Tew JM: Maximizing the extent of tumor resection during transsphenoidal surgery for pituitary macroadenomas: can endoscopy replace intraoperative magnetic resonance imaging? J Neurosurg; 2010 Apr;112(4):736-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maximizing the extent of tumor resection during transsphenoidal surgery for pituitary macroadenomas: can endoscopy replace intraoperative magnetic resonance imaging?
  • OBJECT: Endoscopic approaches to pituitary tumors have become an effective alternative to traditional microscopic transsphenoidal approaches.
  • Despite a proven potential to decrease unexpected residual tumor, intraoperative MR (iMR) imaging is infrequently used even in the few operating environments in which such technology is available.
  • Intrasellar endoscopy was used to determine the presence of residual tumor within the sella turcica and tumor cavity.
  • Intraoperative MR imaging was used to identify rates of unexpected residual tumor and the need for further tumor resection.
  • RESULTS: Intraoperative estimates of the extent of tumor resection were correct in 23 patients (85%).
  • Of 4 patients with unacceptable tumor residuals, 3 underwent further tumor resection.
  • CONCLUSIONS: The findings in this study provided quantitative evidence that intrasellar endoscopy has significant promise for maximizing the extent of tumor resection and is a useful adjunct to surgical approaches to pituitary tumors, particularly when iMR imaging is unavailable.
  • [MeSH-major] Adenoma / pathology. Adenoma / surgery. Endoscopy. Magnetic Resonance Imaging. Pituitary Neoplasms / pathology. Pituitary Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Intraoperative Care. Male. Middle Aged. Neoplasm, Residual / pathology. Neoplasm, Residual / surgery. Retrospective Studies. Sella Turcica / pathology. Sella Turcica / surgery. Sphenoid Bone / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2010 Apr;112(4):734; discussion 735 [19835473.001]
  • (PMID = 19835472.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Shukla D, Behari S, Jaiswal AK, Banerji D, Tyagi I, Jain VK: Tentorial meningiomas: operative nuances and perioperative management dilemmas. Acta Neurochir (Wien); 2009 Sep;151(9):1037-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient had recurrence and four others underwent resurgery for residual tumor.
  • Two patients with petroclival lesions died due to aspiration pneumonitis and meningitis, respectively; one with CP angle TM presented in a poor general condition and expired following emergency ventriculoperitoneal shunt and subsequent definite surgery.
  • Meticulously preserving venous sinuses is important since the risk of venous infarction cannot be predicted even with radiological good venous collaterization and apparent venous sinus blockade by tumor.
  • Laterally situated tumors carry a better prognosis when compared to the medially situated ones.
  • Leaving a small residual tumor in an effort to preserve important neurovascular structures does not obviate the expectation of a good long-term prognosis with minimal morbidity and low recurrence rates.
  • [MeSH-major] Dura Mater / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Postoperative Complications / etiology
  • [MeSH-minor] Adolescent. Adult. Brain Infarction / prevention & control. Brain Stem / blood supply. Brain Stem / pathology. Brain Stem / surgery. Cerebellum / blood supply. Cerebellum / pathology. Cerebellum / surgery. Child. Child, Preschool. Cranial Fossa, Posterior / pathology. Cranial Fossa, Posterior / radiography. Cranial Fossa, Posterior / surgery. Cranial Sinuses / anatomy & histology. Cranial Sinuses / surgery. Decompression, Surgical / methods. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neurosurgical Procedures / methods. Prospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - After Surgery.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19572103.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


61. Ahn JY, Jung JY, Kim J, Lee KS, Kim SH: How to overcome the limitations to determine the resection margin of pituitary tumours with low-field intra-operative MRI during trans-sphenoidal surgery: usefulness of Gadolinium-soaked cotton pledgets. Acta Neurochir (Wien); 2008 Aug;150(8):763-71; discussion 771
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Contrast Media / administration & dosage. Endoscopy / methods. Gadolinium DTPA. Image Enhancement. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Neurosurgical Procedures / methods. Pituitary Neoplasms / surgery. Surgery, Computer-Assisted / methods
  • [MeSH-minor] Administration, Topical. Adolescent. Adult. Aged. Artifacts. Female. Humans. Intraoperative Period. Male. Middle Aged. Neoplasm Invasiveness. Sphenoid Sinus / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18594752.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


62. Andrychowski J, Taraszewska A, Czernicki Z, Jurkiewicz J, Netczuk T, Dabrowski P: Ten years observation and treatment of multifocal pilocytic astrocytoma. Folia Neuropathol; 2009;47(4):362-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathological examinations of the excised foci from spinal canal revealed neoplasm consistent with WHO grade I pilocytic astrocytoma.

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20054789.001).
  • [ISSN] 1509-572X
  • [Journal-full-title] Folia neuropathologica
  • [ISO-abbreviation] Folia Neuropathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


63. Majchrzak H, Krawczyk L, Majchrzak K, Bierzyńska-Macyszyn G: [Surgical treatment of brainstem gliomas and other tumors in adults]. Neurol Neurochir Pol; 2005 Jan-Feb;39(1):27-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of brainstem gliomas and other tumors in adults].
  • BACKGROUND AND PURPOSE: After the introduction of MR imaging to the diagnostics of brainstem tumors and after the introduction of microsurgical procedures to their treatment, the successful treatment, particularly of focal and exophytic forms of these tumors has begun all over the world.
  • The objective of this paper is to establish indications for surgical treatment of gliomas and other tumors of brainstem, to determine surgical approaches and to establish the outcome.
  • MATERIAL AND METHODS: Within the last 6 years, 12 patients with focal and exophytic tumors of the brainstem in adults were operated on.
  • 5 tumors were located in the midbrain, 4 in the pons, 2 in the medulla oblongata and 1 was a cervicomedullary one.
  • With one exception, all tumors were approached via the posterior fossa.
  • A serious complication in 2 patients was bilateral ptosis after the removal of midbrain tumors.
  • CONCLUSIONS: Patients with focal and exophytic forms of the brainstem tumors in MR imaging are qualified for surgical treatment.
  • Immediate results of the treatment depend on the localization and size of the neoplasm.
  • [MeSH-major] Brain Stem Neoplasms / surgery. Glioma / surgery. Neurosurgical Procedures
  • [MeSH-minor] Adult. Brain Neoplasms / surgery. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Minimally Invasive Surgical Procedures / adverse effects. Minimally Invasive Surgical Procedures / methods. Postoperative Complications / prevention & control. Retrospective Studies. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735987.001).
  • [ISSN] 0028-3843
  • [Journal-full-title] Neurologia i neurochirurgia polska
  • [ISO-abbreviation] Neurol. Neurochir. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


64. Bartsch R, Wenzel C, Gampenrieder SP, Pluschnig U, Altorjai G, Rudas M, Mader RM, Dubsky P, Rottenfusser A, Gnant M, Zielinski CC, Steger GG: Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer. Cancer Chemother Pharmacol; 2008 Oct;62(5):903-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four patients (13.8%) developed brain metastases while on therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease Progression. Female. Humans. Middle Aged. Neoplasm Metastasis. Trastuzumab. Treatment Failure


65. Palumbo B, Lupattelli M, Pelliccioli GP, Chiarini P, Moschini TO, Palumbo I, Siepi D, Buoncristiani P, Nardi M, Giovenali P, Palumbo R: Association of 99mTc-MIBI brain SPECT and proton magnetic resonance spectroscopy (1H-MRS) to assess glioma recurrence after radiotherapy. Q J Nucl Med Mol Imaging; 2006 Mar;50(1):88-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of 99mTc-MIBI brain SPECT and proton magnetic resonance spectroscopy (1H-MRS) to assess glioma recurrence after radiotherapy.
  • AIM: The aim of this study was to compare 99mTc-MIBI brain SPECT and proton magnetic resonance spectroscopy (1H-MRS) findings and to evaluate their association.
  • T1/B1 uptake ratio was calculated between a tumor ROI (T1) and a normal mirror symmetric ROI (B1) and T2/B2 ratio was obtained between a ROI in the hottest neoplastic part (T2) and a normal mirror symmetric ROI (B2).
  • SPECT and 1H-MRS disagreed in 2 cases of recurrence (1 diagnosed by brain SPECT, 1 by 1H-MRS).
  • CONCLUSIONS: Brain SPECT and 1H-MRS have equivalent values of diagnostic parameters in differentiating tumor recurrence and radiation effects, and their association might provide additional information.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / radiotherapy. Glioma / metabolism. Glioma / radiotherapy. Magnetic Resonance Spectroscopy / methods. Neoplasm Recurrence, Local / diagnosis. Technetium Tc 99m Sestamibi
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Protons. Radiopharmaceuticals. Statistics as Topic. Tomography, Emission-Computed, Single-Photon / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16557208.001).
  • [ISSN] 1824-4785
  • [Journal-full-title] The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
  • [ISO-abbreviation] Q J Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Protons; 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


66. Liu SF, Zhang S, Chen YC, Fang WF, Lin MC, Su MC, Wang CC: Experience of cancer care for metastasis-induced acute pancreatitis patients with lung cancer. J Thorac Oncol; 2009 Oct;4(10):1231-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology. Pancreatic Neoplasms / secondary. Pancreatitis / drug therapy. Pancreatitis / etiology. Small Cell Lung Carcinoma / secondary
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Bone Neoplasms / therapy. Brain Neoplasms / secondary. Brain Neoplasms / therapy. Female. Humans. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome


67. Bozgunchievz M, Ito K: Avoidable mortality measured by years of potential life lost (YPLL) aged 5 before 65 years in Kyrgyzstan, 1989-2003. Nagoya J Med Sci; 2007 Jan;69(1-2):61-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 2003, this proportion represented 41.5% of the total amount of YPLL due to all the causes studied here, followed by infections and parasitic diseases (12.0%), circulatory disturbance of the brain (11.5%), chronic liver diseases and cirrhosis (11.4%), diseases of the respiratory system (9.2%), and malignant neoplasm of the upper airways and digestive tract (4.6%).
  • The decline in avoidable mortality caused by injury and poisoning, infections disease, malignant neoplasm of the female breast and uterus has to be priority-driven direction for developing Health Policy in the coming years in Kyrgyzstan.
  • Attention also has to be given to reducing of avoidable mortality caused by malignant neoplasm of the female breast by implementing screening programs.
  • [MeSH-minor] Adolescent. Adult. Aged. Cause of Death / trends. Child. Child, Preschool. Female. Humans. Kyrgyzstan. Male. Middle Aged. Neoplasms / mortality. Poisoning / mortality. Population Surveillance. Wounds and Injuries / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378182.001).
  • [ISSN] 0027-7622
  • [Journal-full-title] Nagoya journal of medical science
  • [ISO-abbreviation] Nagoya J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


68. Oh HK, Chambers MS, Martin JW, Lim HJ, Park HJ: Osteoradionecrosis of the mandible: treatment outcomes and factors influencing the progress of osteoradionecrosis. J Oral Maxillofac Surg; 2009 Jul;67(7):1378-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The patients whose ORN was associated with an early-stage tumor or preirradiation extraction had a favorable response to conservative treatment.
  • However, those who had an advanced primary tumor, had continued smoking and drinking after radiotherapy, had received palliative radiotherapy or a radiation dose of more than 6,000 rads, and who had an orocutaneous fistula, a pathologic fracture, swelling, or trismus had a poor response to conservative treatment.
  • CONCLUSIONS: The results of the present study have indicated that several factors (ie, the stage of the primary tumor, signs of ORN) can influence the progress of ORN.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Cranial Irradiation / adverse effects. Mandibular Diseases / therapy. Mouth Neoplasms / radiotherapy. Osteoradionecrosis / therapy
  • [MeSH-minor] Adult. Aged. Debridement. Female. Fractures, Spontaneous / etiology. Humans. Hyperbaric Oxygenation. Male. Mandibular Fractures / etiology. Middle Aged. Neoplasm Staging. Oral Hygiene. Radiotherapy Dosage. Retrospective Studies. Risk Factors. Smoking. Surgical Flaps. Tooth Extraction / adverse effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531406.001).
  • [ISSN] 1531-5053
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Chang-Ming A, Bin Z, Zhen-Gang X, Ping-Zhang T: [Results of stage I and II tongue squamous cell carcinomas treated with different modalities]. Zhonghua Zhong Liu Za Zhi; 2008 Apr;30(4):302-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Tongue Neoplasms / radiotherapy. Tongue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain Neoplasms / secondary. Combined Modality Therapy. Female. Follow-Up Studies. Glossectomy / methods. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neck Dissection. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, High-Energy / methods. Retrospective Studies. Skin Neoplasms / secondary. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18788638.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


70. Brommeland T, Rosengren L, Fridlund S, Hennig R, Isaksen V: Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas. Acta Neurol Scand; 2007 Dec;116(6):380-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Biomarkers, Tumor / blood. Brain Neoplasms / blood. Brain Neoplasms / pathology. Glial Fibrillary Acidic Protein / blood. Glioma / blood. Glioma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain / metabolism. Brain / pathology. Brain / physiopathology. Cell Proliferation. Disease Progression. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Nerve Growth Factors / analysis. Nerve Growth Factors / blood. Predictive Value of Tests. Prognosis. S100 Calcium Binding Protein beta Subunit. S100 Proteins / analysis. S100 Proteins / blood. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986096.001).
  • [ISSN] 0001-6314
  • [Journal-full-title] Acta neurologica Scandinavica
  • [ISO-abbreviation] Acta Neurol. Scand.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Nerve Growth Factors; 0 / S100 Calcium Binding Protein beta Subunit; 0 / S100 Proteins
  •  go-up   go-down


71. Sultan I, Qaddoumi I, Rodríguez-Galindo C, Nassan AA, Ghandour K, Al-Hussaini M: Age, stage, and radiotherapy, but not primary tumor site, affects the outcome of patients with malignant rhabdoid tumors. Pediatr Blood Cancer; 2010 Jan;54(1):35-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age, stage, and radiotherapy, but not primary tumor site, affects the outcome of patients with malignant rhabdoid tumors.
  • BACKGROUND: Malignant rhabdoid tumors (MRTs) are aggressive and often fatal; the Surveillance, Epidemiology, and End Results (SEER) database offers an opportunity to study this rare malignancy.
  • RESULTS: For the 229 patients included in our data, who were diagnosed from 1986 to 2005, primary tumors were located in the central nervous system (CNS) (35%), kidneys (20%), and extra-renal non-cranial sites (ERNC-MRTs) (45%).
  • Most patients with renal and CNS tumors were less than 18 years old (87% and 96%, respectively) while more than half of the patients with ERNC-MRTs (61%) were adults.
  • Among staged tumors, 23% were localized, 34% regional, and 43% distant.
  • Renal tumors had significantly more metastatic disease (47%; P = 0.006) than ERNC-MRTs.
  • Univariate and multivariate analyses showed that age at diagnosis (2-18 years), localized stage of tumors, and use of radiotherapy were significantly associated with improved survival.
  • Adults had a better outcome than young children (<2 years old) but a poorer outcome than older children (2-18 years old); tumor stage, but not radiotherapy use, affected outcome in adults.
  • CONCLUSION: Our population-based study indicates that age at diagnosis, tumor stage, and use of radiotherapy favorably impact survival rates of patients with MRTs.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / radiotherapy. Kidney Neoplasms / pathology. Kidney Neoplasms / radiotherapy. Rhabdoid Tumor / pathology. Rhabdoid Tumor / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Staging. Prognosis. SEER Program. Survival Rate. Treatment Outcome. Young Adult


72. Caloglu M, Yurut-Caloglu V, Karagol H, Bayir-Angin G, Turan FN, Uzal C: Prognostic factors other than the performance status and age for glioblastoma multiforme: a single-institution experience. J BUON; 2009 Apr-Jun;14(2):211-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors other than the performance status and age for glioblastoma multiforme: a single-institution experience.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / therapy. Dacarbazine / analogs & derivatives. Glioblastoma / therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Retrospective Studies. Sex Factors. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19650168.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


73. Schaich M, Kestel L, Pfirrmann M, Robel K, Illmer T, Kramer M, Dill C, Ehninger G, Schackert G, Krex D: A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol; 2009 Jan;20(1):175-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients.
  • BACKGROUND: Some patients with glioblastoma multiform do not respond to temozolomide even though they have aberrant promoter methylation of the DNA repair enzyme O(6)-methylguanine methyltransferase (MGMT).
  • This suggests that additional factors hamper temozolomide cytotoxicity.
  • We aimed to confirm first that temozolomide is a target for the multidrug resistance transporter MDR1/ABCB1 and second to investigate whether genetic variants of the MDR1 gene are associated with the survival of glioblastoma patients treated with temozolomide.
  • MATERIALS AND METHODS: Temozolomide-mediated cytotoxicity was determined by the colorimetric methyl-thiazol-tetrazolium assay in MDR-expressing and MDR-nonexpressing cell lines.
  • Genotypes of three single nucleotide polymorphisms (SNPs) of the MDR1 gene (C1236T, G2677T, and C3435T), MDR1 mRNA expression levels, and the MGMT promoter methylation status were analyzed in 112 glioblastoma patients who had been treated either by surgery plus radiotherapy alone or by additional temozolomide chemotherapy.
  • RESULTS: In vitro analysis revealed that temozolomide-mediated cytotoxicity is dependent on MDR1 expression.
  • Multivariate analysis of MDR1 genotypes showed that the C/C variant of the exon12 C1236T SNP is predictive for survival of patients treated with temozolomide.
  • This effect was independent of the MGMT methylation status.
  • Patients with the C/C genotype had a 2-year overall survival of 37% compared with 8% and 10% for patients with C/T and T/T genotypes, respectively (P=0.02).
  • No influence was seen in the group of patients with radiotherapy only.
  • CONCLUSION: The genotype of the MDR1 exon12 C1236T SNP is a novel independent predictive factor for outcome of temozolomide treatment in glioblastoma patients.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18687982.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Antineoplastic Agents, Alkylating; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


74. Ali SA, McHayleh WM, Ahmad A, Sehgal R, Braffet M, Rahman M, Bejjani G, Friedland DM: Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. J Neurosurg; 2008 Aug;109(2):268-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Glioblastoma / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2012 Feb;116(2):336-40; discussion 340 [22035270.001]
  • (PMID = 18671639.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents, Phytogenic; 2S9ZZM9Q9V / Bevacizumab; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


75. Wheeler CJ, Black KL, Liu G, Mazer M, Zhang XX, Pepkowitz S, Goldfinger D, Ng H, Irvin D, Yu JS: Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res; 2008 Jul 15;68(14):5955-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Posttreatment times to tumor progression (TTP) and survival (TTS) were compared in vaccine responders and nonresponders and were correlated with immune response magnitudes.
  • This is the first report of a progressive correlation between cancer clinical outcome and T-cell responsiveness after therapeutic vaccination in humans and the first tracing of such correlation to therapeutically exploitable tumor alteration.
  • [MeSH-major] Brain Neoplasms / microbiology. Brain Neoplasms / therapy. Glioblastoma / immunology. Glioblastoma / therapy
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / metabolism. Cancer Vaccines. Dendritic Cells / immunology. Female. Humans. Immune System. Leukocytes, Mononuclear / metabolism. Male. Middle Aged. Polymerase Chain Reaction. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18632651.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines
  •  go-up   go-down


76. Burghaus S, Hölsken A, Buchfelder M, Fahlbusch R, Riederer BM, Hans V, Blümcke I, Buslei R: A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas. Virchows Arch; 2010 Mar;456(3):287-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas.
  • Craniopharyngiomas (CP) are benign epithelial tumors of the sellar region and can be clinicopathologically distinguished into adamantinomatous (adaCP) and papillary (papCP) variants.
  • Both subtypes are classified according to the World Health Organization grade I, but their irregular digitate brain infiltration makes any complete surgical resection difficult to obtain.
  • Herein, we characterized the cellular interface between the tumor and the surrounding brain tissue in 48 CP (41 adaCP and seven papCP) compared to non-neuroepithelial tumors, i.e., 12 cavernous hemangiomas, 10 meningiomas, and 14 metastases using antibodies directed against glial fibrillary acid protein (GFAP), vimentin, nestin, microtubule-associated protein 2 (MAP2) splice variants, and tenascin-C.
  • A similar population of presumably astroglial precursors was not visible in other lesions under study, which characterize them as distinct histopathological feature of adaCP.
  • Furthermore, the outer tumor cell layer of adaCP showed a distinct expression of MAP2, a novel finding helpful in the differential diagnosis of epithelial tumors in the sellar region.
  • Our data support the hypothesis that adaCP, unlike other non-neuroepithelial tumors of the central nervous system, create a tumor-specific cellular environment at the tumor-brain junction.
  • Whether this facilitates the characteristic infiltrative growth pattern or is the consequence of an activated Wnt signaling pathway, detectable in 90% of these tumors, will need further consideration.
  • [MeSH-major] Craniopharyngioma / pathology. Pituitary Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Brain / metabolism. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Glial Fibrillary Acidic Protein / metabolism. Humans. Intermediate Filament Proteins / metabolism. Male. Microtubule-Associated Proteins / metabolism. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / physiopathology. Neoplasm Metastasis / pathology. Neoplasm Metastasis / physiopathology. Nerve Tissue Proteins / metabolism. Nestin. Tenascin / metabolism. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1595-603 [17122517.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1997-2001 [12466115.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Dec;28(6):480-8 [12445164.001]
  • [Cites] Endocr Rev. 2006 Jun;27(4):371-97 [16543382.001]
  • [Cites] J Pathol. 2004 Jul;203(3):814-21 [15221941.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 May;7(5):675-87 [17492931.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):778-84 [11533656.001]
  • [Cites] Brain Res. 2002 Jul 12;943(2):174-80 [12101039.001]
  • [Cites] Acta Neurochir (Wien). 2008 Dec;150(12):1213-26 [19002375.001]
  • [Cites] Oncogene. 2005 Dec 8;24(55):8200-4 [16091738.001]
  • [Cites] Glia. 2000 Feb 1;29(3):233-45 [10642750.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3897-904 [8033113.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):89-96 [15146346.001]
  • [Cites] Acta Neuropathol. 2005 Jun;109(6):589-97 [15891929.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Nov 15;139(1):9-17 [12414089.001]
  • [Cites] J Neurochem. 1999 Dec;73(6):2531-7 [10582615.001]
  • [Cites] Glia. 1997 Jan;19(1):35-46 [8989566.001]
  • [Cites] J Biol Chem. 1990 Nov 15;265(32):19679-84 [2174050.001]
  • [Cites] Neurosurgery. 2005 Apr;56(4):763-76 [15792515.001]
  • [Cites] Brain Res Dev Brain Res. 1992 Feb 21;65(2):259-67 [1373996.001]
  • [Cites] Acta Neuropathol. 1978 Sep 15;43(3):191-203 [696237.001]
  • [Cites] Brain Pathol. 2009 Jul;19(3):357-64 [18540944.001]
  • [Cites] Pediatr Neurosurg. 1996 Nov;25(5):240-6; discussion 247 [9309787.001]
  • [Cites] Brain Res Dev Brain Res. 1992 Jul 24;68(1):111-23 [1521317.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10894-8 [7479905.001]
  • [Cites] J Cell Sci. 1994 Nov;107 ( Pt 11):3115-25 [7699010.001]
  • [Cites] Cell Tissue Res. 2003 Dec;314(3):315-24 [14523640.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1 Suppl):3-12 [17233305.001]
  • [Cites] Matrix Biol. 2001 Feb;20(1):13-22 [11246000.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):237-50 [9950494.001]
  • [Cites] J Neurosurg. 1988 Aug;69(2):155-70 [3292716.001]
  • [Cites] Eur J Endocrinol. 2005 Apr;152(4):557-67 [15817911.001]
  • [Cites] J Neurosurg. 1990 Jul;73(1):12-7 [2352012.001]
  • [Cites] Horm Res. 2008;69(4):193-202 [18204266.001]
  • [Cites] Curr Drug Targets CNS Neurol Disord. 2005 Feb;4(1):85-92 [15723616.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):345-51 [11896213.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Apr;62(4):397-409 [15807869.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):984-93 [11589429.001]
  • [Cites] Annu Rev Cell Biol. 1989;5:71-92 [2480799.001]
  • [Cites] Curr Opin Pediatr. 2007 Aug;19(4):471-9 [17630614.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Sep;82(17):6006-9 [3898077.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11771-80 [17178873.001]
  • [Cites] Glia. 1995 Apr;13(4):233-54 [7615335.001]
  • [Cites] Dev Dyn. 2004 May;230(1):1-11 [15108304.001]
  • [Cites] Brain Tumor Pathol. 2005;22(2):75-8 [18095108.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):547-51 [9761047.001]
  • [Cites] Eur J Neurosci. 2005 Oct;22(8):1863-72 [16262626.001]
  • [Cites] Pituitary. 2005;8(2):75-9 [16195780.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1001-10; discussion 1010-1 [7885544.001]
  • [Cites] Acta Neuropathol. 2007 May;113(5):585-90 [17221204.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Mar 31;134(1-2):87-92 [11947939.001]
  • [Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]
  • [Cites] Exp Neurol. 1999 Dec;160(2):348-60 [10619552.001]
  • [Cites] Eur J Endocrinol. 2008 Dec;159 Suppl 1:S95-9 [18775978.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:453-4 [16700324.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2430-9 [14635078.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):206-14 [7616262.001]
  • [Cites] Neuropathology. 2007 Feb;27(1):1-9 [17319278.001]
  • (PMID = 20069432.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / Microtubule-Associated Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Tenascin; 0 / Vimentin
  •  go-up   go-down


77. Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK: A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol; 2007 Feb;81(3):271-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
  • OBJECTIVES: To determine 6-month progression-free survival (6PFS) and toxicity of temozolomide plus thalidomide in adults with recurrent GBM.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Disease-Free Survival. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. North America. Survival Analysis. Thalidomide / therapeutic use

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AAPS J. 2005 Mar 22;7(1):E14-9 [16146335.001]
  • [Cites] Neurology. 2004 Oct 12;63(7):1281-4 [15477552.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):229-43 [15674480.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2675-81 [11555579.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2299-304 [12805330.001]
  • [Cites] Drug Discov Today. 2005 Jan 15;10(2):107-14 [15718159.001]
  • [Cites] Semin Oncol. 2005 Aug;32(4 Suppl 5):S31-5 [16085015.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3B):2481-7 [12894531.001]
  • [Cites] Arch Neurol. 1981 Nov;38(11):696-9 [6975612.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):193-201 [14558594.001]
  • [Cites] Arch Surg. 1975 Aug;110(8):888-91 [1171673.001]
  • [Cites] Surg Neurol. 1998 Feb;49(2):189-95; discussion 196 [9457270.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Am J Med. 1983 Aug;75(2):289-94 [6881181.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):353-7 [15380566.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1481-91 [10735896.001]
  • [Cites] J Neurooncol. 1994;19(3):245-50 [7807175.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] FEBS J. 2005 Nov;272(22):5723-41 [16279938.001]
  • [Cites] Semin Oncol. 2001 Aug;28(4 Suppl 13):43-6 [11550138.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):31-8 [11763420.001]
  • [Cites] Immunopharmacology. 1996 Mar;31(2-3):213-21 [8861747.001]
  • [Cites] Neurosurgery. 2003 Sep;53(3):639-60; discussion 660-1 [12943581.001]
  • [Cites] Front Biosci. 2003 Jan 01;8:d100-16 [12456339.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):708-15 [10673511.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):635-44 [15497116.001]
  • [Cites] J Exp Med. 1993 Jun 1;177(6):1675-80 [8496685.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] J Neurooncol. 1994;18(3):207-16 [7964981.001]
  • (PMID = 17031561.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / CA62399; United States / NCI NIH HHS / CA / CA62412; United States / NCI NIH HHS / CA / CA62422; United States / NCRR NIH HHS / RR / M01-RR00042; United States / NCRR NIH HHS / RR / M01-RR00056; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCRR NIH HHS / RR / M01-RR0865; United States / NCI NIH HHS / CA / U01CA62405; United States / NCI NIH HHS / CA / U01CA62407
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


78. Moulin-Romsée G, D'Hondt E, de Groot T, Goffin J, Sciot R, Mortelmans L, Menten J, Bormans G, Van Laere K: Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine? Eur J Nucl Med Mol Imaging; 2007 Dec;34(12):2082-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine?
  • BACKGROUND: Static imaging of amino acids does not allow differentiation of low versus high grade brain tumours.
  • METHODS: Thirty-four patients with primary brain glioma and histopathological confirmation were retrospectively studied using 40 min dynamic MET-PET with 220 MBq 11C-methionine.
  • [MeSH-major] Brain Neoplasms / diagnostic imaging. Brain Neoplasms / pathology. Glioma / diagnostic imaging. Glioma / pathology. Methionine. Positron-Emission Tomography / methods
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Neoplasm Staging. Radiopharmaceuticals. Reproducibility of Results. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2002 Nov;225(2):567-74 [12409596.001]
  • [Cites] J Nucl Med. 2001 Aug;42(8):1144-50 [11483672.001]
  • [Cites] J Nucl Med. 2001 Mar;42(3):432-45 [11337520.001]
  • [Cites] NeuroRx. 2005 Apr;2(2):333-47 [15897954.001]
  • [Cites] J Nucl Med. 2006 Mar;47(3):393-403 [16513607.001]
  • [Cites] Oncologist. 2006 Feb;11(2):165-80 [16476837.001]
  • [Cites] EMBO J. 2002 Feb 15;21(4):580-9 [11847106.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):422-9 [15650870.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Aug;33(8):932-9 [16604346.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Aug;27(7):1432-7 [16908552.001]
  • [Cites] J Nucl Med. 1999 Jan;40(1):205-12 [9935078.001]
  • (PMID = 17763978.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 58576-49-1 / carbon-11 methionine; AE28F7PNPL / Methionine
  •  go-up   go-down


79. Strojnik T, Kavalar R, Barone TA, Plunkett RJ: Experimental model and immunohistochemical comparison of U87 human glioblastoma cell xenografts on the chicken chorioallantoic membrane and in rat brains. Anticancer Res; 2010 Dec;30(12):4851-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: The U87 cell suspension was inoculated onto the chick chorioallantoic membrane on embryonic day seven and into the brain of nude rats.
  • Brain tumour sections were examined for various known tumour markers by routine haematoxylin and eosin staining and immunohistochemical analyses.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / pathology. Chorioallantoic Membrane / pathology. Disease Models, Animal. Glioblastoma / pathology
  • [MeSH-minor] Adult. Animals. Chick Embryo. Female. Humans. Immunohistochemistry. Neoplasm Transplantation. Rats. Rats, Nude. Spheroids, Cellular. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187462.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


80. Jiang F, Xu L, Yuan FL, Huang JF, Lu XX, Zhang XY: [Lung auto-transplantation technique in the treatment for stage III central lung cancer]. Zhonghua Yi Xue Za Zhi; 2010 May 18;90(19):1329-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the length of resected bronchus or pulmonary artery involved by tumor was too long to perform tension-free anastomosis, we transplanted the inferior pulmonary vein to the proximal stump of the superior pulmonary vein.
  • Until Jan 2008, six of the eight patients who underwent lung autotransplantations, had been free of tumor recurrence for 7-90 months with good quality of life.
  • Another patient died of brain metastases 31 months postoperatively.
  • [MeSH-major] Lung Neoplasms / surgery. Lung Transplantation / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Transplantation, Autologous


81. Reni M, Zaja F, Mason W, Perry J, Mazza E, Spina M, Bordonaro R, Ilariucci F, Faedi M, Corazzelli G, Manno P, Franceschi E, Pace A, Candela M, Abbadessa A, Stelitano C, Latte G, Ferreri AJ: Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer; 2007 Mar 26;96(6):864-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide as salvage treatment in primary brain lymphomas.
  • Methotrexate (MTX)-based chemotherapy extends survival in patients with primary brain lymphomas, but it is not clear whether multiagent chemotherapy is superior to MTX alone.
  • Treatment options for patients with recurrent primary brain lymphoma are limited; there is no standard second-line chemotherapy.
  • New chemotherapeutic agents with clear activity in brain lymphoma are needed for treatment of recurrent disease.
  • We report the results of a phase II trial assessing activity of the alkylating agent temozolomide in immunocompetent patients with recurrent primary brain lymphomas, previously treated with high-dose MTX-containing chemotherapy and/or radiotherapy.
  • We conclude that temozolomide is active in recurrent primary brain lymphomas and should further be evaluated in this disease, perhaps in combination with MTX as initial treatment.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Lymphoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • [Cites] Ann Oncol. 2006 Jul;17(7):1141-5 [16603598.001]
  • [Cites] Leuk Lymphoma. 2003 Apr;44(4):627-33 [12769339.001]
  • [Cites] Ann Oncol. 2000 Aug;11(8):927-37 [11038028.001]
  • [Cites] Neurology. 2002 May 28;58(10):1513-20 [12034789.001]
  • [Cites] Eur J Haematol. 2003 Apr;70(4):219-24 [12656744.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):530-4 [10027325.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2407-14 [12805341.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1165-7; authir reply 1167-8 [15020628.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(11):1682-8 [15251157.001]
  • [Cites] Neurology. 2004 Sep 14;63(5):901-3 [15365145.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Ann Oncol. 1997 Mar;8(3):227-34 [9137790.001]
  • [CommentIn] Nat Clin Pract Oncol. 2007 Sep;4(9):514-5 [17622233.001]
  • (PMID = 17325700.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Other-IDs] NLM/ PMC2360092
  •  go-up   go-down


82. Vredenburgh JJ, Cloughesy T, Samant M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Das A, Friedman HS: Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist; 2010;15(12):1329-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.
  • We assessed corticosteroid use in patients with recurrent glioblastoma treated with bevacizumab (BEV) in the BRAIN study (J Clin Oncol 2009;27:4733-4740).
  • METHODS: BRAIN was a phase II, multicenter, randomized, noncomparative trial of BEV alone (n = 85) or in combination with irinotecan (CPT-11) (n = 82) in adults with recurrent glioblastoma.
  • [MeSH-major] Adrenal Cortex Hormones / therapeutic use. Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Bevacizumab. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Survival Rate. Treatment Outcome. Vascular Endothelial Growth Factor A / antagonists & inhibitors. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Drugs. 1995 Feb;6(1):19-33 [7756680.001]
  • [Cites] Biochem Pharmacol. 1999 Jul 15;58(2):363-8 [10423179.001]
  • [Cites] J Neurooncol. 2006 Dec;80(3):313-32 [16807780.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Neurology. 2008 Mar 4;70(10):779-87 [18316689.001]
  • [Cites] J Neurooncol. 2009 Feb;91(3):329-36 [18953493.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • (PMID = 21147867.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ PMC3227925
  •  go-up   go-down


83. Takahashi S, Kawase T, Yoshida K, Hasegawa A, Mizoe JE: Skull base chordomas: efficacy of surgery followed by carbon ion radiotherapy. Acta Neurochir (Wien); 2009 Jul;151(7):759-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thus far, 3 patients have died from the neoplasms.
  • The 3 year recurrence free survival rates of carbon ion therapy treated group was 70.0%, being higher than that of the other groups treated with radiotherapy or untreated (57.1%, and 7.1% respectively).
  • [MeSH-major] Chordoma / therapy. Skull Base Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Brain Stem / radiation effects. Brain Stem / surgery. Carbon Radioisotopes / therapeutic use. Child. Combined Modality Therapy. Female. Humans. Ions / therapeutic use. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Optic Nerve / radiation effects. Optic Nerve / surgery. Postoperative Complications / prevention & control. Radiation Dosage. Radiation Injuries / prevention & control. Radiotherapy / methods. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19434365.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 0 / Ions
  •  go-up   go-down


84. Chuang CF, Chan AA, Larson D, Verhey LJ, McDermott M, Nelson SJ, Pirzkall A: Potential value of MR spectroscopic imaging for the radiosurgical management of patients with recurrent high-grade gliomas. Technol Cancer Res Treat; 2007 Oct;6(5):375-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When combined with patient survival data, metabolic information obtained during follow-up MRSI studies seemed to indicate the potential to help to distinguish necrosis from new/recurrent tumor; however, this should be further verified by biopsy studies.
  • [MeSH-major] Brain Neoplasms / surgery. Glioma / surgery. Magnetic Resonance Spectroscopy / methods. Neoplasm Recurrence, Local / surgery. Radiosurgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Contrast Media / administration & dosage. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Tumor Burden

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17877425.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


85. Idowu OE, Apemiye RA: Delay in presentation and diagnosis of adult primary intracranial neoplasms in a tropical teaching hospital: a pilot study. Int J Surg; 2009 Aug;7(4):396-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delay in presentation and diagnosis of adult primary intracranial neoplasms in a tropical teaching hospital: a pilot study.
  • Sixty-three adult patients with intracranial neoplasms were studied prospectively over a 2 year period.
  • Meningiomas (30%), Pituitary tumours (18%), High-grade gliomas (14%) and craniopharyngiomas (8%) were the most common brain tumours.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / mortality. Cause of Death. Health Services Accessibility. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Developing Countries. Early Detection of Cancer. Female. Hospitals, Teaching. Humans. Immunohistochemistry. Male. Middle Aged. Needs Assessment. Neoplasm Staging. Nigeria. Pilot Projects. Prospective Studies. Risk Assessment. Survival Analysis. Time Factors. Tropical Climate. Young Adult


86. Peters P, Bandi H, Efendy J, Perez-Smith A, Olson S: Rapid growth of cervical cancer metastasis in the brain. J Clin Neurosci; 2010 Sep;17(9):1211-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid growth of cervical cancer metastasis in the brain.
  • Cervical cancer rarely metastasises to the brain, with occurrences of approximately 0.77%.
  • Our patient was referred for treatment of a brain lesion on the background of known metastatic cervical cancer to the lungs and new onset seizure activity.
  • The brain is an increasingly common site for metastases of cervical cancer and must be considered when staging these patients.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / secondary. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Cell Proliferation. Female. Humans. Neoplasm Staging. Time Factors


87. Micallef J, Taccone M, Mukherjee J, Croul S, Busby J, Moran MF, Guha A: Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression. Cancer Res; 2009 Oct 1;69(19):7548-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme (GBM) is the most common and most malignant adult brain tumor.
  • [MeSH-major] Brain Neoplasms / enzymology. Glioblastoma / enzymology. Membrane Proteins / biosynthesis. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Epidermal Growth Factor / pharmacology. Humans. Intracellular Signaling Peptides and Proteins / genetics. Intracellular Signaling Peptides and Proteins / metabolism. Mice. Neoplasm Invasiveness. Protein Kinase C-alpha / metabolism. RNA, Small Interfering / genetics. Signal Transduction. Transfection

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19773446.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / RNA, Small Interfering; 0 / epidermal growth factor receptor VIII; 125267-21-2 / myristoylated alanine-rich C kinase substrate; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.13 / Protein Kinase C-alpha
  •  go-up   go-down


88. Nakamura H, Takeshima H, Makino K, Kochi M, Ushio Y, Kuratsu J: Recurrent intracranial germinoma outside the initial radiation field: a single-institution study. Acta Oncol; 2006;45(4):476-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Until 1991, patients with pure germinomas or germinomas with syncytiotrophoblastic giant cells (STGCs) received whole-brain radiotherapy only.
  • Of the 52 patients, 30 were treated with a reduced radiation volume and combined chemotherapy; seven of these received local irradiation with 24 Gy, two received whole-brain (30 Gy) plus local irradiation (20 Gy), 16 received extended local irradiation delivered to the whole ventricles (30 Gy) plus local (20 Gy) irradiation, and five received extended local irradiation (24 Gy).
  • Of the 30 patients treated with a reduced radiation volume and combined chemotherapy, four experienced tumor recurrence; three patients had been treated with 24 Gy of local radiotherapy and one had received extended local (30 Gy) plus local (20 Gy) irradiation in addition to chemotherapy.
  • In these patients, the delivered radiotherapy was inadequate and the origin of the recurrent tumors was outside the radiation field.
  • None of the patients who had received at least 24 Gy of whole ventricle radiotherapy combined with chemotherapy experienced tumor recurrence.
  • In combination with chemotherapy, the delivery of irradiation covering the ventricles effectively reduced the incidence of tumor recurrence in patients with germinomas or germinomas with STGCs.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Germinoma / radiotherapy. Neoplasm Recurrence, Local / diagnosis. Neoplasms, Radiation-Induced / diagnosis
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Radiation Dosage. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Germinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16760185.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


89. Homma A, Oridate N, Suzuki F, Taki S, Asano T, Yoshida D, Onimaru R, Nishioka T, Shirato H, Fukuda S: Superselective high-dose cisplatin infusion with concomitant radiotherapy in patients with advanced cancer of the nasal cavity and paranasal sinuses: a single institution experience. Cancer; 2009 Oct 15;115(20):4705-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteonecrosis (n=7), brain necrosis (n=2), and ocular/visual problems (n=16) were observed as late adverse reactions.
  • [MeSH-major] Cisplatin / administration & dosage. Nasal Cavity. Nose Neoplasms / drug therapy. Nose Neoplasms / radiotherapy. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / adverse effects. Disease Progression. Female. Humans. Infusions, Intra-Arterial. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Analysis. Thiosulfates / administration & dosage

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • (PMID = 19634162.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thiosulfates; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


90. Pittock SJ, Parisi JE, McKeon A, Roemer SF, Lucchinetti CF, Tan KM, Keegan BM, Hunter SF, Duncan PR, Baehring JM, Matsumoto JY, Lennon VA: Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri). Arch Neurol; 2010 Sep;67(9):1109-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antibodies, Neoplasm / immunology. Brain / pathology. Dystonic Disorders / immunology. Jaw / immunology. Laryngismus / immunology. Paraneoplastic Syndromes / immunology
  • [MeSH-minor] Adult. Aged. Antibodies, Antinuclear / immunology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Dystonia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Neurol. 2011 Mar;68(3):399 [21403033.001]
  • (PMID = 20837856.001).
  • [ISSN] 1538-3687
  • [Journal-full-title] Archives of neurology
  • [ISO-abbreviation] Arch. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ANNA-2 antibody, human; 0 / Antibodies, Antinuclear; 0 / Antibodies, Neoplasm
  •  go-up   go-down


91. Oechsle K, Kollmannsberger C, Honecker F, Boehlke I, Bokemeyer C: Cerebral metastases in non-seminomatous germ cell tumour patients undergoing primary high-dose chemotherapy. Eur J Cancer; 2008 Aug;44(12):1663-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Brain Neoplasms. Neoplasms, Germ Cell and Embryonal. Testicular Neoplasms
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Clinical Trials, Phase II as Topic. Combined Modality Therapy / methods. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Multicenter Studies as Topic. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Retrospective Studies. Salvage Therapy / methods. Stem Cell Transplantation. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cancer. 2008 Aug;44(12):1622-4 [18653329.001]
  • (PMID = 18620855.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


92. Plotkin M, Gneveckow U, Meier-Hauff K, Amthauer H, Feussner A, Denecke T, Gutberlet M, Jordan A, Felix R, Wust P: 18F-FET PET for planning of thermotherapy using magnetic nanoparticles in recurrent glioblastoma. Int J Hyperthermia; 2006 Jun;22(4):319-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Brain Neoplasms / therapy. Glioblastoma / therapy. Hyperthermia, Induced / methods. Magnetics. Nanostructures. Neoplasm Recurrence, Local / therapy. Positron-Emission Tomography / methods. Tyrosine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Radiotherapy Planning, Computer-Assisted

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16754352.001).
  • [ISSN] 0265-6736
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / O-(2-fluoroethyl)tyrosine; 42HK56048U / Tyrosine
  •  go-up   go-down


93. Johnson N, Sermer M, Lausman A, Maxwell C: Obstetric outcomes of women with intracranial neoplasms. Int J Gynaecol Obstet; 2009 Apr;105(1):56-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obstetric outcomes of women with intracranial neoplasms.
  • OBJECTIVE: To determine the obstetric outcomes of women diagnosed with a primary intracranial neoplasm prior to or during pregnancy and the puerperium.
  • Thirteen patients were diagnosed prior to pregnancy (group 1); tumor growth or recurrence during pregnancy occurred in 3 patients.
  • [MeSH-major] Brain Neoplasms / complications. Pregnancy Complications, Neoplastic / physiopathology. Pregnancy Outcome
  • [MeSH-minor] Adult. Cesarean Section / statistics & numerical data. Databases, Factual. Female. Glioma / complications. Glioma / physiopathology. Glioma / surgery. Humans. Infant, Newborn. Intensive Care Units, Neonatal / statistics & numerical data. Meningioma / complications. Meningioma / physiopathology. Meningioma / surgery. Neoplasm Recurrence, Local / epidemiology. Ontario / epidemiology. Postpartum Period. Pregnancy. Premature Birth / etiology. Retrospective Studies. Vision Disorders / epidemiology. Vision Disorders / etiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19155008.001).
  • [ISSN] 1879-3479
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Benouaich-Amiel A: [Clinical diagnosis of infiltrating gliomas in the adult]. Soins; 2009 Mar;(733):30-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical diagnosis of infiltrating gliomas in the adult].
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioma / diagnosis
  • [MeSH-minor] Adult. Biopsy. Epilepsy / etiology. Humans. Intracranial Hypertension / etiology. Magnetic Resonance Imaging. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19365997.001).
  • [ISSN] 0038-0814
  • [Journal-full-title] Soins; la revue de référence infirmière
  • [ISO-abbreviation] Soins
  • [Language] fre
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


95. Kiewe P, Fischer L, Martus P, Thiel E, Korfel A: Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis. Cancer; 2008 Apr 15;112(8):1812-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 60 patients treated with HDMTX-based chemotherapy, the treatment of 9 was followed with whole-brain irradiation.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Central Nervous System Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Methotrexate / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cranial Irradiation. Disease Progression. Disease-Free Survival. Feasibility Studies. Female. Follow-Up Studies. Humans. Karnofsky Performance Status. Longitudinal Studies. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18318432.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


96. Ray WZ, Blackburn SL, Casavilca-Zambrano S, Barrionuevo C, Orrego JE, Heinicke H, Dowling JL, Perry A: Clinicopathologic features of recurrent dysembryoplastic neuroepithelial tumor and rare malignant transformation: a report of 5 cases and review of the literature. J Neurooncol; 2009 Sep;94(2):283-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of recurrent dysembryoplastic neuroepithelial tumor and rare malignant transformation: a report of 5 cases and review of the literature.
  • Dysembryoplastic neuroepithelial tumors (DNETs) have traditionally been viewed as benign "quasihamartomatous" tumors widely considered curable with surgery alone.
  • These findings suggest that these patients may need closer follow-up than initially suggested, lending further support to the notion that this tumor behaves more like a benign neoplasm, rather than a dysplastic or hamartomatous lesion.
  • [MeSH-major] Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasms, Neuroepithelial / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Magnetic Resonance Imaging. Male. Young Adult


97. McClelland S 3rd, Libien JM, Chin SS, Adams DJ, Resor SR Jr, Chan S, Goodman RR: Unusual findings in brain biopsies of two patients with acute magnetic resonance imaging lesions associated with focal seizures. Epilepsia; 2005 Sep;46(9):1495-501
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual findings in brain biopsies of two patients with acute magnetic resonance imaging lesions associated with focal seizures.
  • PURPOSE: Patients with focal seizures often have magnetic resonance imaging (MRI) abnormalities in the brain region of their presumed seizure focus.
  • Neoplasms, ischemic infarctions, inflammatory processes, and other specific pathologic entities have been diagnosed by biopsies of such MRI abnormalities.
  • Two patients with this presentation had brain lesion biopsies with a leading presumptive diagnosis of glial neoplasm but were found to have indistinct histopathology.
  • CONCLUSIONS: We describe two patients who had brain biopsies of striking focal increased T2 signal MRI abnormalities associated with seizures.
  • Pathologic findings contradicted our preoperative suspicions (neoplasm or inflammatory process), compatible with (but not conclusive for) subacute venous congestion/thrombosis.
  • [MeSH-major] Brain / pathology. Epilepsies, Partial / pathology. Magnetic Resonance Imaging / statistics & numerical data
  • [MeSH-minor] Adult. Biopsy, Needle. Brain Diseases / pathology. Brain Diseases / surgery. Craniotomy. Female. Gliosis / pathology. Hemosiderosis / pathology. Hippocampus / pathology. Humans. Male. Middle Aged. Preoperative Care. Stereotaxic Techniques. Treatment Outcome. Venous Thrombosis / pathology

  • Genetic Alliance. consumer health - Seizures.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16146445.001).
  • [ISSN] 0013-9580
  • [Journal-full-title] Epilepsia
  • [ISO-abbreviation] Epilepsia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Qian ZY, Wu YY, Huang Q, Zhai DZ, Zhu Q, Wang AD, Huo HM, Lan Q: [Expression of SV40Tag, Rb and IRS-1 in glioma detected by tissue microarray and their relation with tumorigenesis and progression of gliomas]. Zhonghua Zhong Liu Za Zhi; 2008 Jun;30(6):432-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tissue microarrays were constructed containing 118 samples including human glioma and meningioma, experimental glioma, and normal human brain tissue.
  • RESULTS: The expressions of SV40Tag, Rb and IRS-1 were detected in gliomas and benign brain tumors.
  • Their positive expression rate in glioma was 65.9%, 64.6% and 48.8%, respectively, with a statistically non-significant difference between the malignant and benign brain tumors.
  • In the normal human brain tissue only the expression of Rb (77.8%, 7/9) and IRS-1 (22.2%, 2/9) were detected, but expression of SV40Tag could not be observed.
  • CONCLUSION: Our findings that no expression of SV40Tag was observed in normal human brain tissue indicates that expression of SV40Tag may play an important role in the pathogenesis of glioma.
  • [MeSH-major] Antigens, Polyomavirus Transforming / metabolism. Brain Neoplasms / metabolism. Glioma / metabolism. Insulin Receptor Substrate Proteins / metabolism. Retinoblastoma Protein / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. Brain / metabolism. Brain / pathology. Cell Line, Tumor. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Meningioma / metabolism. Meningioma / pathology. Mice. Middle Aged. Neoplasm Transplantation. Rats. Rats, Sprague-Dawley. Tissue Array Analysis. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19024517.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / IRS1 protein, human; 0 / Insulin Receptor Substrate Proteins; 0 / Retinoblastoma Protein
  •  go-up   go-down


99. Kubo O, Chernov M, Izawa M, Hayashi M, Muragaki Y, Maruyama T, Hori T, Takakura K: Malignant progression of benign brain tumors after gamma knife radiosurgery: is it really caused by irradiation? Minim Invasive Neurosurg; 2005 Dec;48(6):334-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant progression of benign brain tumors after gamma knife radiosurgery: is it really caused by irradiation?
  • Malignant transformation of benign neoplasm after radiosurgery is usually diagnosed based on the initial presence of benign tumor, its exposure to ionizing radiation, elapsed time from radiation exposure to malignant progression, and different histological characteristics or growth rate of the regrowing tumor comparing with those originally treated.
  • Three presented cases fulfilled these diagnostic criteria; however, it seems that progression of the tumors (schwannoma, meningioma, chordoma) resulted from the natural course of the disease, rather than represented side effects of gamma knife radiosurgery.
  • Evaluation of the proliferative potential of the benign neoplasm before radiosurgical treatment either directly, if tumor sampling is available, or indirectly, by calculation of the tumor growth rate and/or analysis of the data of the metabolic imaging (PET, MRS) is important for identification of "aggressive" subtypes, precise prediction of prognosis, and confirmation of the radiation-induced malignant transformation in cases of tumor regrowth.
  • [MeSH-major] Brain Neoplasms / surgery. Cell Transformation, Neoplastic / radiation effects. Chordoma / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasms, Radiation-Induced / physiopathology. Neurilemmoma / surgery. Radiosurgery / adverse effects
  • [MeSH-minor] Adult. Brain Diseases / surgery. Cell Proliferation. Female. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16432782.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


100. Patel AJ, Suki D, Hatiboglu MA, Abouassi H, Shi W, Wildrick DM, Lang FF, Sawaya R: Factors influencing the risk of local recurrence after resection of a single brain metastasis. J Neurosurg; 2010 Aug;113(2):181-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors influencing the risk of local recurrence after resection of a single brain metastasis.
  • OBJECT: Local recurrence (LR) of a resected brain metastasis occurs in up to 46% of patients.
  • Postoperative whole-brain radiation therapy (WBRT) reduces that incidence.
  • METHODS: The authors reviewed data from 570 cases involving patients who had undergone resection of a previously untreated single brain metastasis at The University of Texas M. D.
  • All tumors were measured preoperatively on MR images.
  • Tumors exceeding the median volume (9.7 cm(3)) had a significantly higher LR risk than those that were < 9.7 cm(3) (crude HR 1.7; 95% CI 1.1-2.6; p = 0.02).
  • In the multivariate analysis, small tumors removed by EBR had a significantly lower LR risk.
  • CONCLUSIONS: The LR risk of a single brain metastasis is influenced by biological factors (such as tumor volume) and treatments (such as the resection method).
  • Early administration of postoperative WBRT may be particularly warranted when such negative tumor-related prognostic factors are noted or when treatment-related ones such as PMR are unavoidable.
  • [MeSH-major] Brain Neoplasms. Neoplasm Recurrence, Local / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Incidence. Male. Middle Aged. Multivariate Analysis. Postoperative Care. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Factors. Severity of Illness Index. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2010 Aug;113(2):179; discussion 179-80 [20035573.001]
  • (PMID = 20035574.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement